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ABSTRACT

Objectives – To measure the effect of non – asthmatic atopy (NAA) on the risk of adverse pregnancy
outcomes; low birth weight (LBW), small for gestational age (SGA) and preterm birth (PTB), among
primiparous women 19 – 25 years of age.

Methods – Vital Statistics records from births occurring between 2004 and 2014, from approximately
60,000 primiparous women in South Carolina, aged 19 to 25 years, were linked to their Medicaid
records. Maternal records were examined to determine if they had a previous diagnosis of NAA. Women
with a diagnosis of NAA were frequency matched with a ratio of 1:4 to non – atopic controls by age, sex
of infant, and asthma diagnosis. Next, the frequencies of LBW, SGA and PTB were compared across the
two groups of women. Tests for linear trend across birth weight categories and gestational age at birth
categories were then conducted after which separate Poisson regression models were estimated to
measure the risk of each outcome.

Results – Linear tests for increasing trend were statistically significant (p < 0.001); indicating that higher
percentages of NAA are associated with higher infant birth weight. Similarly, higher percentages of NAA
were associated with greater gestational age at birth. After controlling for maternal race/ethnicity,
smoking during pregnancy, gestational diabetes and pre – pregnancy hypertension; mothers with a
diagnosis of NAA had reduced risk for each outcome (RR = 0.96, 0.94 and 0.95 for LBW, SGA and

ix

PTB respectively). These results were not statistically significant (p > 0.05). Similar results were seen when
data was further explored by maternal race/ethnicity.

Conclusions – NAA could promote a healthy pregnancy and reduce the risk of adverse outcomes and
should therefore be taken into account when assessing a woman’s risk of same. Until now this protection
has gone unnoticed due to the increase in the risk of study outcomes that are associated with a diagnosis
of asthma, and the fact that in many instances asthma is present with NAA. Additional analyses are
needed to evaluate unknown factors associated with its diagnosis and treatment.

x

CHAPTER ONE: INTRODUCTION

There is an increasing trend of allergic sensitization among children and young adults which
has been documented since the 1990s (Deckers et al., 2012). This sensitization is responsible for
disorders such as allergic rhinitis, atopic dermatitis as well as eczema (Deckers et al., 2012; Ruby
Pawankar, Canonica, Holgate, & Lockey, 2012). Atopic disorders are the most common chronic
diseases in the developed world (Ruby Pawankar et al., 2012). The prevalence of atopic dermatitis
(AD) has doubled or tripled in industrialized countries over the last three decades (Bieber, 2008;
Simpson et al., 2001). Allergic rhinitis (AR) affects between 10% to 30% of the world’s population
(AAAAI, 2015; Ruby Pawankar, Walter Canonica, Holgate, & Lockey, 2011). With increasing
trends comes the need to better understand how allergic sensitization and suffering from chronic
allergies affect the human body. One very visible effect of this worsening phenomenon is the
increased burden that it places on the health care sector in the form of doctor visits and prescription
costs (Franzese, 2011). There is also an impact on the economy due to loss of productivity from
absenteeism, time spent away from work, and/or those same doctor visits (Franzese, 2011).
Productivity losses that are due to presenteeism can also be seen, where employees are on the job
but underperform due to experiencing allergic symptoms (Lamb et al., 2006; Zuberbier, Lötvall,
Simoens, Subramanian, & Church, 2014)
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Another visible effect of this worsening phenomenon is how atopic symptoms, namely
asthma during pregnancy affects birth outcomes. Researchers have found that uncontrolled asthma
during pregnancy can lead to adverse pregnancy outcomes such as low birth weight (LBW) and
preterm birth (PTB) (Firoozi et al., 2010; V. Murphy et al., 2011; Trønnes et al., 2014). There are
few studies that have addressed the effect of other atopic disorders, non – asthmatic atopy (NAA);
allergic rhinitis and atopic dermatitis, have on a developing fetus and the final outcome of
pregnancy.
The increasing prevalence of these conditions make it important to address the question of
their effect on pregnancy as a woman’s risk of adverse outcomes may be influenced by a diagnosis of
non – asthmatic atopy.

1.1

STATEMENT OF THE PROBLEM
Atopic disorders are the most common chronic diseases in the developed world (Ruby

Pawankar et al., 2012). The prevalence of atopic dermatitis has doubled or tripled in industrialized
countries over the past three decades (Bieber, 2008; Simpson et al., 2001). Allergic Rhinitis affects
up to one – third of the world’s population (Ruby Pawankar et al., 2011). There is a gap in the
current literature on how non – asthmatic atopy affects pregnancy outcomes. Therefore this study
examined the association between maternal atopic disorders and pregnancy outcomes.

Research Question 1
Does non – asthmatic atopy in women adversely affect pregnancy outcomes?
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Hypothesis 1
There are differences in the risk of adverse pregnancy outcomes between primiparous women
who have non – asthmatic atopy and those who don’t.

Research Question 2
Does maternal race/ethnicity modify the effect of non – asthmatic atopy on pregnancy
outcomes?

Hypothesis 2
There are differences in the way that maternal race/ethnicity affects pregnancy outcomes
between primiparous women with non – asthmatic atopy and those without.

3

CHAPTER TWO: REVIEW OF THE LITERATURE

2.1

PREGNANCY
During the first trimester of pregnancy, the fetus neural tube (brain and spinal cord) is well

formed. Other systems such as the digestive tract and sensory organs begin to develop during this
time, and bone begins to replace cartilage. Towards the end of the first trimester, the fetus circulatory
and urinary systems are functional. The most critical development of the fetus takes place during
the first trimester and the chance of miscarriage is greatly reduced after 13 weeks of pregnancy.
Due to a number of reasons, some mothers may experience adverse outcomes at the end of
their pregnancy. Adverse outcomes include having an infant born with low birth weight (LBW),
(weighing less than 2500 grams or 5.5 pounds at birth), very low birth weight (weighing less than
1500 grams or 3.33 pounds at birth) being born pre – term, Preterm Birth (PTB), (less than 37
weeks gestation), very pre – term (less than 32 weeks of gestation) or being born with a birth defect
as well as stillbirth (CDC, 2014a, 2014b). Another adverse pregnancy outcome is intra – uterine
growth restriction or being born small for gestational age (SGA) (Clayton et al., 2007). It is known
that birth weight is positively correlated to gestational age. The SGA statistic takes into account
gestational age at birth when measuring birth weight of a newborn. A newborn with a birth weight
less than the 10th percentile for their gestational age and gender is considered to be SGA (CDC,
2014b). Because birth weights are very population specific, other researchers have classified infants
as being SGA if they have a birth weight less than 2 standard deviations from the sex – and
4

gestational age – specific mean, of their study sample (Trønnes et al., 2014). These outcomes; low
birth weight, small for gestational age, and preterm birth are associated with further issues during
childhood and survival into adulthood. Other health indicators of fetal wellbeing at birth include
Apgar score (Apgar, 1952). The Apgar score ranges between 0 and 10 with scores below 7 indicating
an adverse pregnancy outcome. Issues such as survival, developmental delays, failure to thrive, as
well as severe disability are more prevalent among this population of babies (Anderson et al., 2011;
Kelleher et al., 1993; Kotecha et al., 2012; Lindström, Lindblad, & Hjern, 2011).
Several risk factors for adverse pregnancy outcomes have been identified. Risk factors
including maternal characteristics such as: chronic diseases; e.g. hypertension (Lindheimer, 1993)
and diabetes (Arulkumaran, 2011). It is well documented that hypertension during pregnancy has
the potential to escalate causing pre – eclampsia leading to intra – uterine growth restriction and
preterm birth (Lindheimer, 1993; Vest & Cho, 2012). Pre – existing Type I and Type II diabetes as
well as gestational diabetes increase the risk of intra – uterine growth restriction which leads to low
birth weight, macrosomia and stillbirth (Casson et al., 1997; Yogev & Visser, 2009). These
conditions are also risk factors for poor health outcomes in the mother (Arulkumaran, 2011).
Uncomplicated obesity in the mother still puts her at risk for macrosomia in her offspring as well as
increasing her risks of developing hypertension and diabetes (Yogev & Visser, 2009). It is also well
documented that smoking during pregnancy increases the risk of adverse outcomes for the fetus
such as, low birth weight, small for gestational age as well as preterm birth (Ko et al., 2014;
SILVERMAN, 1977). Other maternal characteristics that influence pregnancy outcomes include
maternal age and number of previous pregnancies. Expectant mothers considered to be at higher
risk may be more closely monitored to better ensure the best possible outcome. In such cases
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increased monitoring and access to early intervention may be the best assets to ensure the best
possible outcome for both the mother and the child.
Adverse pregnancy outcomes such as low birth weight (Fuentes-Afflick & Lurie, 1997; James,
1993) and preterm birth (CDC, 2013b) are disproportionately distributed across race/ethnicity. The
2013 prevalence of low birth weight was 7.0%, 13.1% & 7.1% for white, black and Hispanic women
respectively (CDC, 2014b). The 2013 prevalence of preterm birth was 10.8%, 17.1% and 11.8% for
white, black and Hispanic women respectively (CDC, 2013b). After controlling for obesity,
hypertension, diabetes and prenatal care, black women (adjusted OR = 2.5) and Hispanic women
(adjusted OR = 1.4) had an increased risk for delivering an infant prematurely when compared to
white women (Johnson, Rottier, Luellwitz, & Kirby, 2009).

2.2

ATOPY
Atopy can be defined as the genetic tendency to develop allergic disorders such as asthma,

allergic rhinitis (AR) and atopic dermatitis (AD) (AAAAI, 2015). Allergic rhinitis, more commonly
referred to as hay fever and atopic dermatitis, more commonly referred to as eczema, are also
generally referred to as allergies. The rates of these disorders are increasing worldwide (Ruby
Pawankar et al., 2012). In the United States there are approximately 17.2 million (8.7%) adults and
4.6 million (6.5%) children with asthma (CDC, 2013a). The prevalence of asthma is higher among
women (10.7%) when compared to men (6.5%) (CDC, 2013a).
Asthma is a chronic disorder that affects the airways and is associated with atopy. These
airways are inflamed in people with asthma and they are sensitive to triggers (AAAAI, 2015). When
exposed to a trigger, the increased sensitivity leads to an immune response which is at first dominated
6

by T – helper 1 cells (associated with airway inflammation) and later on is dominated by T – helper
2 cells (associated with mucus production) (Bergqvist et al., 2015). During asthmatic symptom flare
ups, a person usually finds it difficult to breathe. Asthma can be an indicator of the presence of
other atopic disorders such as allergic rhinitis (AR) and atopic dermatitis (AD). Between 30% and
80% of asthma patients also reported having AR (Kim, Bouchard, & Renzix, 2008) while 40% of
patients with AR also reported having asthma (Kim et al., 2008). However, even with suspected
under diagnosis of atopy (Greiner, Hellings, Rotiroti, & Scadding, 2012), persons may have only
one atopic disorder and may never develop or display any symptoms of the others.
Allergic rhinitis (AR) is a disorder of the nose characterized by a T – helper 2 cell dominated
immune response after exposure to an allergen (Bousquet et al., 2012; Feng, Miller, & Simon, 2012;
Rondón et al., 2012). This response usually produces symptoms such as sneezing, nasal congestion
and runny nose (Bousquet et al., 2012; Skoner, 2001). Allergens such as dust, mold and mites can
trigger symptoms which is largely an overreaction to the irritant. Allergic rhinitis is not a serious
disorder and anti – histamine as well as intranasal corticosteroids have been used to treat the
symptoms (Greiner et al., 2012). It has been postulated that while not a serious disease on its own,
AR can put a person at risk for developing asthma, or, symptom flare ups of previously diagnosed
asthma (Bousquet et al., 2012; Greiner et al., 2012). The presence of AR can be confirmed with a
skin prick test (SPT) (Feng et al., 2012; Rondón et al., 2012).
Atopic Dermatitis (AD) is a chronic or recurrent inflammatory skin disease (AAAAI, 2015;
Akdis et al., 2006). It has a complex pathogenesis which includes skin barrier dysfunction and
allergy/immunological responses (Kabashima, 2013). AD symptoms usually flare up due to T –
helper 2 mediated immune responses to different triggers (Hijnen et al., 2013). In chronic cases a
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person’s skin does not appear normal due to tissue remodeling caused by severe inflammation (Akdis
et al., 2006).
Atopic disorders are the most common chronic diseases present in the developed world
(Simpson et al., 2001). While their precise mechanism is not fully understand there are many factors
that contribute to the development and manifestation of atopic symptoms. There are still questions
as to whether the likelihood of developing atopy increases or decreases with increased sibship
(Karmaus & Botezan, 2002; Rona, Duran-Tauleria, & Chinn, 1997). There has also been ethnic
differences noted in the prevalence and type of atopic symptoms observed with allergic rhinitis and
other allergies affecting the airways more prevalent in European and Australian countries (Hjern,
Haglund, & Hedlin, 2000), and atopic dermatitis being more prevalent in African countries
(Williams et al., 1999).
In the United States approximately 20 – 25% of the general adult population, between the
ages of 16 – 65, is affected by an allergic disorder (Franzese, 2011; Sibbald & Rink, 1991). While
there is increasing knowledge about these disorders, the circumstances leading to the development
or exacerbation of atopy are not fully understood. Researchers have identified many environmental
risk factors that can lead to the worsening of allergic symptoms experienced in the population. Air
quality has been identified as an important environmental risk factor in modifying symptoms of
allergies. When air quality is low and there is exposure to air pollutants, allergic symptoms and other
manifestations of allergies can be exacerbated (Strachan, Wong, & Spector, 2001; Wyler et al.,
2000). Allergens and irritants that are present in personal environments (e.g. home) such as
fragrances, pet and animal dander can worsen allergic symptoms (Simpson et al., 2001). Typically,
the symptoms associated with allergic sensitization are worse during childhood as the immune
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system has an immature response to allergens. The National Center for Health Statistics (NCHS)
data brief; Trends in Allergic Conditions among Children: United States 1997 – 2011 (Jackson,
Howie, & Akinbami, 2013), states that the prevalence of respiratory related allergies in children is
approximately 17% which represents an increasing trend over previous decades (Jackson et al.,
2013). In the past, allergic symptoms decreased as children got older which led to a smaller
prevalence of allergies among adults. Trends found among young adults could be due to the type of
allergy symptom being examined. Younger children are more likely to have skin allergies, while older
children and young adults are more likely to have respiratory allergies (Jackson et al., 2013). An
argument could therefore be made that the prevalence of respiratory allergies increases with age
which would explain the higher rates being exhibited in adults. In addition to this, there are
increasing trends in the prevalence of respiratory allergies worldwide (Dotterud & Smith‐Sivertsen,
2007). Furthermore, many adults have reported that they became sensitized for the first time in
adulthood (Schäfer et al., 2001).
Doctors and other health care providers are faced with the challenge of prescribing
medications that will relieve symptoms and which cause few side effects even when taken for a
relatively long period of time. Prescription therapy for treating atopic dermatitis and eczema are
varied in the literature (Akdis et al., 2006; Hanifin, Ling, Langley, Breneman, & Rafal, 2001).
Treatment for atopic dermatitis should comprise of optimal skin care, promoting skin repair and
hydration, along with avoidance of known triggers (Akdis et al., 2006). Treatment is also largely
dependent on the severity of symptoms (Greiner et al., 2012). Treatment for allergic rhinitis is
similarly varied. It ranges from simple nasal treatments such as saline nasal irrigation
(Hermelingmeier, Weber, Hellmich, Heubach, & Mösges, 2012) to intra – nasal corticosteroids
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(Greiner et al., 2012). Patient perception of the side effects of particular medication can also
influence the outcome of treatment and even with the best treatment options one in five patients
remain highly symptomatic (Greiner et al., 2012). In addition, patients may not always comply with
treatment medication as they fear adverse events associated with the medications prescribed
(Hellings et al., 2012).

2.3

ATOPY DURING PREGNANCY

2.3.1

ASTHMA
Asthma is the most common chronic disease that affects women during pregnancy (Maselli,

Adams, Peters, & Levine, 2013) and it can have a significant impact on the outcome of the pregnancy
(Aly et al., 2011; V. Murphy et al., 2011). During pregnancy, changes occur in a woman’s pulmonary
physiology such as, minute ventilation (the amount of air entering the lungs each minute) increasing
due to the higher levels of progesterone which are present in her body (Maselli et al., 2013).
In their review article and subsequent meta – analysis, Murphy et al found that maternal
asthma was associated with adverse pregnancy outcomes affecting the newborn such as low birth
weight (LBW) and preterm birth (PTB) (V. Murphy et al., 2011). They found that asthma in mothers
led to a 46% increase in the risk of low birth weight, a 22% increase in the risk of the infant being
born small for gestational age (SGA) and a 41% increase in the risk of preterm birth (V. Murphy et
al., 2011). Asthma during pregnancy also led to adverse maternal outcomes such as complicated
labor and pregnancy induced hypertension (V. Murphy et al., 2011). Firoozi et al also found similar
results in that maternal asthma was associated with an increase in the odds of SGA and PTB (Firoozi
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et al., 2010). The mechanism on how asthma could cause these adverse outcomes is not fully
understood. However, due to the sequelae associated with asthmatic symptom flare ups, it has been
postulated that maternal hypoxemia as well as the changing functions carried out by the placenta,
led to the adverse maternal and fetal outcomes among asthmatic women during pregnancy (V. E.
Murphy, Clifton, & Gibson, 2006). The effect of demographic factors such as Socioeconomic status
(SES) is also not clearly understood (Firoozi et al., 2010). Bakhireva et al found that poorly controlled
asthma in pregnant women puts them at an increased risk for preterm delivery and suggests that
adequate treatment protocols and access to health care are necessary to maintain optimal asthma
control and lessen adverse outcomes (Bakhireva, Schatz, Jones, & Chambers, 2008).
Asthma surveillance data indicates that the prevalence of asthma is disproportionately
distributed by race/ethnicity with 9.9% of African Americans/Blacks reporting a diagnosis of
asthma while 7.6% of Whites and 6.7% of Hispanics reporting a diagnosis of asthma (CDC, 2013a).
Murphy et al in their meta – analysis noted that due to regional differences observed, ethnic
disparities are plausible (V. Murphy et al., 2011). While Aly et al in their 2011 study found that
maternal asthma was associated with low birth weight outcomes in black non – Hispanic women
(BNH) but not white non – Hispanic women (WNH) (Aly et al., 2011). They found that BNH
women with asthma had a significant increase in the odds (OR = 1.7; p < 0.05) of low birth weight
compared to BNH without asthma. While there was no statistically significant difference in the odds
of low birth weight among WNH women with asthma compared to WNH women without asthma
(OR = 0.99; p > 0.05) (Aly et al., 2011). However, Aly and colleagues did not account for the severity
of asthma nor did they account for medication used for asthma control.
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There is conflicting evidence about using medication to control asthma during pregnancy.
Hodyl et al found that using Inhaled Corticosteroids (ICS) significantly impacted maternal
glucocorticoid – regulated systems and not fetal system and furthermore, this impact was only
demonstrated when pregnant with a female (Hodyl et al., 2011). They also found that fetal
adrenaline functions were not significantly affected by maternal ICS use (Hodyl et al., 2011) and as
such would not affect fetal growth and development. While this study suggests that ICS use poses
minimal harm to fetal development, it does indicate that ICS use does have some effect on the
woman. Nonetheless, Lim et al (Lim, Stewart, Abramson, & George, 2011) found that health care
providers were hesitant to prescribe ICS to patients with asthma during pregnancy and McCusker
et al (McCusker & Hamid, 2011) concluded that ICS use during pregnancy continued to be a
concern for potential adverse outcomes for the pregnant woman and the developing fetus. This
suggests that more research needs to be conducted to determine the best standard of care and
treatment practice for women with asthma during pregnancy.

2.3.2

ALLERGIC RHINITIS (AR) AND ATOPIC DERMATITIS (AD)
The effect of these maternal atopic disorders on pregnancy outcomes is not completely

known or understood. Studies conducted so far, that have investigated the effect of these atopic
disorders have found them to be significantly associated with a reduction in adverse pregnancy
outcomes. Savilhati et al. found that the odds of mothers being diagnosed with Allergic Rhinitis
(AR) was reduced by 50% (OR = 0.49; 95% CI 0.26 – 0.89) among infants born extremely low birth
weight (less than 1000 g) and the odds of being diagnosed with Atopic Dermatitis (AD) was reduced
by 36% (OR = 0.64; 95% CI 0.36 – 1.15) among ELBW (Savilahti, Siltanen, Pekkanen, & Kajosaari,
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2004). Another study found that AR in mothers was associated with a reduced risk of congenital
abnormalities (CA) by 30% (prevalence OR = 0.7; 95% CI 0.6 – 0.9) (Somoskövi et al., 2007).
A recent study by Trønnes et al conducted on a Norwegian cohort found that maternal non
– asthmatic atopy is associated with a protective effect for preterm birth, still birth and neonatal
death and further that maternal asthma was associated with an increased risk of preterm birth
(Trønnes et al., 2014). Asthma diagnosed in mothers increased the odds of preterm birth 15%, while
AD and AR in mothers reduced the risk of same by 10% and 16% respectively (Trønnes et al., 2014).
Atopy in pregnant women can also affect the overall development of the child. Croen et al,
found that children whose mothers experienced atopy; including allergic rhinitis and atopic
dermatitis were at an increased risk for being diagnosed with Autism Spectrum Disorders (ASD)
(Croen, Grether, Yoshida, Odouli, & Van de Water, 2005). They further found evidence indicating
that the timing of exposure modified this risk. They found that children whose mothers had any
history of atopy had an increased risk of ASD and further that those whose mothers experienced
atopic exacerbation during their second trimester of pregnancy were at a greater than 2 fold increased
risk for developing ASD (Croen et al., 2005).
Maternal atopy has been found to be associated with various outcomes in child development.
It has been linked to the child’s immune responses stimuli (Amoudruz et al., 2005) and it has also
been identified as a risk factor for the development of atopy in their offspring (Krauss-Etschmann et
al., 2006; Pali-Schöll, Renz, & Jensen-Jarolim, 2009; Reece et al., 2011).
Studies on the effect of maternal atopy on fetal and child development up to this point have
mainly focused on allergic sensitization in the child (Krauss-Etschmann et al., 2006; Pali-Schöll et
al., 2009; Reece et al., 2011). Few have explored other adverse outcomes manifesting later on in life
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such as ASD (Croen et al., 2005). Fewer have been conducted in the United States exploring the
effect of non – asthmatic atopy on adverse pregnancy outcomes.

2.4

REVIEW OF METHODS USED IN THE LITERATURE
To characterize the effect of various atopic disorders including asthma, allergic rhinitis and

atopic dermatitis, on pregnancy outcomes, standard statistical analytic methods have been employed,
while researchers have utilized administrative databases to identify their study population. These
studies have also used samples of varying size from 207 (Hodyl et al., 2011) to approximately
2,000,000 (Trønnes et al., 2014).

2.4.1

DATA SOURCES
Researchers have utilized various data sources such as linking information found in National

Registries from over many decades (Trønnes et al., 2014) or linking information found in regional
administrative databases for national health insurance programs (Firoozi et al., 2010). Aly et al were
able to sample from a perinatal database of women delivering at a Medical Center (Aly et al., 2011).
While, Hodyl et al prospectively recruited 207 pregnant women at their first visit to an antenatal
clinic (Hodyl et al., 2011).

2.4.2

DEFINITION AND MEASUREMENT OF EXPOSURE
In their study Trønnes et al identified allergic rhinoconjunctivitis using International

Classification of Diseases ICD – 10 codes J30.1 – J30.4 and H10.1 and ICD – 8 code 507 (Trønnes
et al., 2014). Atopic dermatitis was identified using ICD – 10 code L20 or where used ICD – 8 codes
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691 and 692 (Trønnes et al., 2014). Asthma was identified using ICD – 10 code J45, ICD – 8 codes
491 and 493) (Trønnes et al., 2014) and ICD – 9 code 493 (Firoozi et al., 2010). Other studies
interviewed patients and classified them as having atopy based on self – reported history or
documented history of same (Savilahti et al., 2004), while others only included patients who
experienced exacerbations during pregnancy (Aly et al., 2011; Somoskövi et al., 2007). Hodyl et al
used a diagnosis of asthma as documented by a physician (Hodyl et al., 2011). Asthma medication
was indicated dichotomously as yes or no depending on whether or not there was a prescription by
a physician on the patient’s chart (Hodyl et al., 2011).

2.4.3

DEFINITION AND MEASUREMENT OF OUTCOMES
Outcomes that have been examined include: preterm birth; still birth; and, neonatal death.

Studies for the most part have used the global definitions of these routinely measured outcomes. A
preterm birth was generally defined as a birth that occurred before completing the 37th week of
gestation (Aly et al., 2011; Firoozi et al., 2010; Trønnes et al., 2014) . Small for gestational age (SGA)
was defined as having a birth weight below 2 standard deviations from the mean of the sample
according to gestational age and sex (Trønnes et al., 2014) or as a birth weight below the 10th
percentile for gestational age and gender (Aly et al., 2011; Firoozi et al., 2010; Hodyl et al., 2011). A
neonatal death was defined as death occurring within 28 days after a live birth (Trønnes et al., 2014).
Blood samples were taken to measure clinical indicators of fetal and maternal functions when the
mother took medication to treat her asthma symptoms while pregnant. (Hodyl et al., 2011).
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2.4.4

STATISTICAL ANALYSIS
Data analysis has employed the use of chi – square tests for bivariate associations (Aly et al.,

2011; Firoozi et al., 2010; Hodyl et al., 2011; Trønnes et al., 2014). Multivariable analyses used to
quantify effects while controlling for other factors, included repeated measures log – binomial
regression models (Trønnes et al., 2014) and logistic regression models (Aly et al., 2011; Firoozi et
al., 2010). Hodyl et al performed log transformations, and employed the use of repeated measures
ANOVA on the transformed birth weight data to describe the effect of medication on pregnancy
outcomes (Hodyl et al., 2011).
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CHAPTER THREE: METHODOLOGY

3.1

STATEMENT OF RESEARCH QUESTIONS

3.1.1

NON – ASTHMATIC ATOPY (NAA) AND PREGNANCY OUTCOMES
This study seeks to determine if there exists an association between a diagnosis of maternal

non – asthmatic atopy (NAA); allergic rhinitis (AR) and atopic dermatitis (AD), and adverse
pregnancy outcomes; low birth weight (LBW), small for gestational age (SGA) and preterm birth
(PTB).

Research Question 1
Does maternal NAA adversely affect pregnancy outcomes?

Example of models to be fit:
i)

Among entire study sample

Preterm Birth (Yes/No) ~ Maternal NAA – AR (Yes/No) | other predicting factors

ii)

Among infants born after completing 37 weeks of gestation

Low Birth Weight (Yes/No) ~ Maternal NAA – AD (Yes/No) | other predicting factors
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3.1.2

NON

–

ASTHMATIC

ATOPY

(NAA)

AND

PREGNANCY

OUTCOMES

BY

RACE/ETHNICITY

This study seeks to determine if maternal race/ethnicity; White Non – Hispanic (WNH) or
Black Non – Hispanic (BNH), modifies the effect of NAA on adverse pregnancy outcomes.

Research Question 2
Does maternal race/ethnicity modify the adverse effect of NAA on pregnancy outcomes?

Example of Models to be fit:
iii)

Among WNH women and BNH women separately

SGA (Yes/No) ~ Maternal NAA – AD (Yes/No) | other predicting factors
PTB (Yes/No) ~ Maternal NAA – AR (Yes/No) | other predicting factors

3.1.3

STUDY POPULATION
The study population is comprised of primiparous women between the ages of 19 and 25.

3.1.4

INCLUSION CRITERIA
The women included in this study were primiparous and between the ages of 19 and 25 years

old.
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3.1.5

EXCLUSION CRITERIA
Excluded from this study were women who were, younger than 19 years old or older than

25 years. Women were also excluded if they were multiparous or had a plural birth. In addition to
this, fetuses born before the completion of 24 weeks of gestation were excluded.

3.1.6

DATA SOURCES
An administrative database was used in order to generate a higher absolute number of

mothers with the disorders being studied. The database that was used to answer the research
question was identified retrospectively using South Carolina’s MEDICAID database. These claims
were linked to births occurring between January 1, 2004 and January 1, 2014 identified in South
Carolina’s Vital Statistics records.

3.1.7

DEFINITION AND MEASUREMENT OF EXPOSURE AND OUTCOMES
The diagnosis being measured is non – asthmatic atopy (NAA). Women were classified as

having the diagnosis or not. Women were classified as having NAA using ICD – 9 code 477 for
allergic rhinitis (AR) and/or ICD – 9 codes 691 and 692 for atopic dermatitis (AD) at least 1 year
prior to pregnancy. Births from the women identified were matched to State birth records to classify
the outcome of the pregnancy. Additional information that was extracted from the database include
maternal characteristics that serve as possible confounders. These include diagnoses of asthma,
hypertension and diabetes. Additional confounding demographic and risk factors that were
extracted include race/ethnicity and smoking.
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Mothers with the diagnosis being studied, NAA, were frequency matched to 4 unexposed
mothers according to age, sex of the infant born and a diagnosis of asthma.
The outcomes being investigated in this study are low birth weight (LBW), small for
gestational age (SGA) and preterm birth (PTB). Infants were classified as: having low birth weight
(LBW) if their birth weight was less than 2500g. Infants with a birth weight less than the 2 standard
deviations from the sex – and gestational age – specific mean of the dataset were classified as being
SGA. While births occurring before completion of the 37th week of gestation were classified as a
preterm birth (PTB).

3.1.8

STATISTICAL ANALYSIS
Statistical analysis was conducted using STATA version 12 (StataCorp, 2011). Each

individual contributed a single observation (only first pregnancy) to the analysis and therefore
standard methods for data analysis on numeric outcomes and categorical outcomes were employed.
In the first instance, data was summarized. Then bivariate associations were measured using T –
tests, Chi – Square tests or Fisher’s exact tests depending on tabulation frequencies. Associations
found were quantified using Poisson regression models.

3.1.9

SAMPLE SIZE AND POWER
In order to be sufficiently able to measure a change in risk, the sample must have adequate

power to detect this change (see Tables 1 – 6).
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Using a population prevalence rate for low birth weight of 8% (CDC, 2014b) the tables
below show the required sample size with corresponding power to detect various multiples of risk of
the outcome in the exposed population.
Using the MEDICAID database, there was sufficient sample size to have 85% power to detect
a 50% increase as well as 80% power to detect a 40% reduction in the risk of low birth weight
(LBW), using a matching ratio of 1 diagnosed NAA mother to 4 NAA undiagnosed controls.
Using a population prevalence rate for preterm birth (PTB) of 12.5% (CDC, 2014b) the
tables below shows the required sample size with corresponding power to detect various multiples
of risk of the outcome in the exposed population.
Using the MEDICAID database, there should be a sufficient sample size to have 90% power
to detect a 50% increase as well as a 40% reduction in risk of preterm birth, using a matching ratio
of 1 diagnosed NAA mothers to 4 NAA undiagnosed controls.

3.2

REGULATORY PERMISSIONS

This study, ID Pro00020127, was approved by the University of South Florida’s Institutional Review
Board (IRB) (Appendix J). In addition, permission was also obtained from the South Carolina
Department of Health and Environmental Control to use their Medicaid and Vital Statistics records
(Appendix K).
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3.3

CHAPTER THREE TABLES AND FIGURES

Table 1: Sample Size Calculation for Low Birth Weight; matching ratio 1:1
Increased
Risk

Power

80%
exposed controls
2x
283
283
1.5x
932
932
0.6x
979
979
Population LBW prevalence = 8.0%
Type I error rate = 5%

85%
Exposed
Controls
320
320
1058
1058
1111
1111

90%
exposed controls
370
370
1230
1230
1290
1290

Table 2: Sample Size Calculation for Low Birth Weight; matching ratio 1:2
Increased
Risk

Power

80%
Exposed
controls
2x
204
408
1.5x
682
1364
0.6x
755
1510
Population LBW prevalence = 8.0%
Type I error rate = 5%

85%
exposed controls
233
466
779
1558
851
1702

90%
exposed
controls
271
542
911
1822
981
1962

Table 3: Sample Size Calculation for Low Birth Weight; matching ratio 1:4
Increased
Risk

Power

80%
Exposed controls
2x
164
256
1.5x
557
2228
0.6x
641
2564
Population LBW prevalence = 8.0%
Type I error rate = 5%

85%
exposed
Controls
188
752
639
2556
719
2876
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90%
exposed controls
221
884
750
3000
824
3296

Table 4: Sample Size Calculation for Preterm Birth; matching ratio 1:1
Increased
Risk

Power

80%
85%
exposed controls
exposed Controls
2x
168
168
190
190
1.5x
561
561
637
637
0.6x
604
604
685
685
Population PTB prevalence = 12.5%
Type I error rate = 5%

90%
exposed Controls
219
219
739
739
794
794

Table 5: Sample Size Calculation for Preterm Birth; matching ratio 1:2
Increased Power
Risk
80%
85%
exposed controls
exposed
2x
122
244
139
1.5x
412
824
469
0.6x
465
930
524
Population PTB prevalence = 12.5%
Type I error rate = 5%

Controls
278
938
1048

90%
exposed
controls
161
322
548
1096
604
1208

Table 6: Sample Size Calculation for Preterm Birth; matching ratio 1:4
Increased
Risk

Power

80%
85%
exposed controls
exposed Controls
2x
98
392
112
448
1.5x
336
1344
385
1540
0.6x
394
1576
442
1768
Population PTB prevalence = 12.5%
Type I error rate = 5%
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90%
exposed controls
132
528
452
1808
507
2028

CHAPTER FOUR: RESULTS

4.1

SUMMARY OF SAMPLE CHARACTERISTICS
The Medicaid database contained 67,281 unique maternal records. The Vital Statistics

database contained 67,771 infant outcomes. During data cleaning some records from the infant
outcomes were excluded. These were 1,369 records from plural births, 543 records with information
on plurality missing, 165 records with gestational ages at birth less than 24 weeks, 38 records with
gestational age at birth missing and 8 records with infant birth weight missing (see Appendix E,
Figure 13). This left 65,650 infant outcomes which were then linked to the 67,281 maternal records
using a unique identifier present in both databases. This formed 65,650 (97.5% of the 67,281
maternal records) complete maternal – infant dyads for analysis. Of these 65,650 mother – infant
dyads there were 1,993 diagnosed with NAA who were frequency matched 1:4 to undiagnosed
controls on maternal age, maternal diagnosis of asthma and infant sex. The dataset used in the
primary analysis contained the 9,965 matched records (see Appendix E, Figure 14).
Table 26 (see Appendix F) provides a summary of the International Classification of Disease
Codes (ICD – 9) used in this study.
Mothers’ ages ranged from 19 to 25 years with a mean of 20.8 yrs. (see Appendix F, Table
27). There were 1,993 (20.0%) mothers with a diagnosis of non – asthmatic atopy (NAA) and 7,972
unexposed controls (Table 7). One thousand and ninety three (11.1%) mothers had a diagnosis of
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allergic rhinitis (AR) and 959 (9.6%) had a diagnosis of atopic dermatitis (AD) (Table 7). Infants’
gestational ages at birth ranged from 24 to 43 weeks with a mean of 38.6 weeks. Infants’ birth weights
ranged from 140 to 6,719 grams with a mean of 3,155.1 grams (see Appendix F, Table 27). The
number of non – asthmatic atopy diagnoses among mothers ranged from 0 to 4 (see Appendix F,
Table 27).
Figure 1 displays the percentage of mothers with NAA across infant birth weight. Non –
asthmatic atopy (AR and AD combined), along with AR (considered separately) (see Appendix G,
Figure 15) and AD (considered separately) (see Appendix G, Figure 16), all displayed a significant
increasing trend across birth weight categories. Approximately 16% of infants born, weighing less
than 1,000 grams, had mothers with NAA compared to 20% of infants born weighing 2,500 grams
or more (Figure 1). Figures 15 and 16 (see Appendix G) also show that among mothers who had
heavier infants at birth, higher percentages were diagnosed with AR and AD. While asthma
displayed a significant decreasing trend across birth weight (Figure 2). Mothers with heavier infants
at birth had lower percentages with asthma. Figure 3 displays the percentage of mothers with NAA
across gestational ages at birth categories. There is a significant increasing trend across gestational
age at birth. Mothers who gave birth later had higher percentages with NAA. Approximately 14%
of infants born between 24 and 27 weeks of gestation, had mothers with NAA compared to 20% of
those born after completing at least 36 weeks of gestation. Figure 4 displays the percentage of
mothers with NAA across fetuses at risk for each gestational age (i.e. fetuses who were born with a
greater gestational age). There is a significant overall increasing trend as well as a significant
increasing trend up to 36 weeks of gestation. After 40 weeks of gestation, the percentage of mothers
with NAA decreases. Figure 17 (see Appendix G) displays the percentage of mothers with AR across
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gestational ages at birth categories. There is a significant increasing trend across gestational age at
birth. Mothers who gave birth later had higher percentages with AR. Figure 18 (see Appendix G)
displays the percentage of mothers with AR across fetuses at risk for each gestational age. There is a
significant overall increasing trend as well as a significant increasing trend up to 36 weeks of
gestation. Figure 19 (see Appendix G) displays the percentage of mothers with AD across gestational
ages at birth categories. There is a significant increasing trend across gestational age at birth. Mothers
who gave birth later had higher percentages with AD. Figure 20 (see Appendix G) displays the
percentage of mothers with AD across fetuses at risk for each gestational age. There is a significant
overall increasing trend as well as a significant increasing trend up to 36 weeks of gestation. Figure
5 displays the percentage of mothers with asthma across gestational ages at birth categories. There is
a significant decreasing trend across gestational age at birth. Mothers who gave birth later had lower
percentages with asthma. Figure 6 displays the percentage of mothers with asthma across fetuses at
risk for each gestational age. There is a significant overall increasing trend as well as a significant
increasing trend up to 36 weeks of gestation.
There were slightly more males born (51.6%) than females (48.4%) (see Appendix F, Table
28). The sample included 4,607 (46.3%) White non – Hispanic (WNH) mothers, 4,556 (45.7%)
Black non – Hispanic mothers (BNH), 698 (7.0%) Hispanic mothers, and 100 (1.0%) mothers who
were of another race/ethnicity or whose race/ethnicity was given as other (see Appendix F, Table
28). Approximately one – fifth (19.5%) of women reported smoking prior to pregnancy, while 14.7%
reported smoking during pregnancy (see Appendix F, Table 28). Pre – pregnancy diabetes was
reported in 0.7% of women, while almost 5 times as many (3.3%) were reported to have gestational
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diabetes. Pre – pregnancy hypertension was reported among 2.0% of women and 15.5% had a
previous diagnosis of asthma (see Appendix F, Table 28).
Among infants born at term; at least 37 weeks of gestation, the percent with LBW was 4.4%
(Table 8). The percent of infants born SGA was 2.0% in this sample and the percent of PTB; infants
born before completing 37 weeks of gestation was 9.5%.

4.2

SUMMARY OF CHARACTERISTICS BY ATOPY CATERGORY

4.2.1

NON – ASTHMATIC ATOPY (NAA)
Table 29 (see Appendix F) shows the distributions of age of mother, gestational age of infant

at birth and infant birth weight. There was no difference in mean gestational age at birth or infant
birth weight among mothers with NAA and those without. There was a lower proportion of mothers
with NAA who were of Hispanic ethnicity when compared to the proportion of mothers without
NAA who were of Hispanic ethnicity (3.3% vs. 7.9% resp.; p < 0.001), while there were almost equal
proportions of WNH and BNH mothers in either atopy category (see Appendix F, Table 30). The
percent of mothers who smoked prior to pregnancy was higher among mothers with NAA compared
to those without NAA (21.4% vs. 19.0%; p < 0.05). While the percent of mothers who smoked
during pregnancy, had pre – pregnancy diabetes, gestational diabetes, pre – pregnancy hypertension
and asthma; was similar across NAA diagnosis (see Appendix F, Table 30).
There was no difference in distribution of study outcomes, LBW, SGA or PTB among
mothers with NAA and those without (Table 9).
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The distribution of characteristics were similar when examined as type of NAA i.e. Allergic
Rhinitis (AR) and Atopic Dermatitis (AD) (see Appendix F, Table 31). A maternal diagnosis of
asthma and maternal race/ethnicity were significantly associated with type of NAA (Table 10). There
was a higher proportion of mothers with asthma among patients with AR when compared to those
without (21.2% vs. 14.8% resp.; p < 0.001) (Table 10). The relationship between asthma and AD
was reversed, a smaller proportion of mothers with AD also had asthma when compared to those
who did not have AD (10.4% vs. 16.1% resp.; p < 0.001) (Table 10).
A higher proportion of mothers with AR were WNH compared to the proportion of those
who did not have AR (52.3% vs. 45.5% resp.) (Table 10). This pattern was reversed for mothers of
other ethnicities; BNH (44.7% vs. 45.9% resp.), Hispanic (2.6% vs. 7.6% resp.) and other (0.4% vs.
1.1% resp.). Among mothers with AD a larger proportion were BNH when compared to the
proportion of mothers without AD who were (52.9% vs. 45.0%). Again this pattern was reversed
among mothers of other ethnicities; WNH (42.4% vs. 46.7% resp.), Hispanic (4.0% vs. 7.3% resp.)
and other (0.7% vs. 1.0% resp.).
Table 11 shows the distribution of study outcomes across atopy type.

4.2.2

ASTHMA
Mothers who had previously been diagnosed with Asthma were similar in age to those who

had not previously been diagnosed with asthma (see Appendix F, Table 29). The mean gestational
age at birth was slightly lower among mothers who had been previously diagnosed with asthma when
compared to those who had not (38.4 weeks vs. 38.6 weeks, p < 0.001). Infants born to mothers with

28

asthma weighed less than those born to mothers without asthma (3096.6 g vs. 3166.7 g, p < 0.001)
(see Appendix F, Table 29).
There was a higher proportion of BNH mothers with asthma compared to the proportion of
BNH mothers without asthma (51.5% vs. 44.7% resp.) (see Appendix F, Table 30). While a smaller
proportion of mothers with asthma were Hispanic than the proportion of mothers without asthma
who were (3.6% vs. 7.6% resp.). The percent who smoked prior to pregnancy was higher among
mothers with asthma compared to mothers without (23.4% vs. 18.8% resp.; p < 0.001). This was
also true of smoking during pregnancy (18.8% vs. 14.0% resp.; p < 0.001). The percent with pre –
pregnancy diabetes was higher among mothers with asthma than it was among mothers without
asthma (1.3% vs. 0.6% resp.; p < 0.05), while the percent with gestational diabetes was similar for
both groups of women. Pre – pregnancy hypertension was also higher among mothers with asthma
when compared to those without asthma (3.1% vs. 1.8%; p < 0.05) (see Appendix F, Table 30).
Table 9 shows the associations between study outcomes and asthma. Birth weight when
explored as extremely low birth weight (less than 1,000g), very low birth weight (1,000 – 1,499g),
moderately low birth weight (1,500 – 2,499g), normal birth weight (2,500 – 3,999g) and high birth
weight (4,000g or more); did display a significant association with having a diagnosis of asthma or
not. However when birth weight was explored as simply low birth weight (less than 2,500g) among
infants born at term (at least 37 weeks of gestation), there was no association with a diagnosis of
asthma. There was also no association found between infants born SGA and mothers with a previous
diagnosis of asthma or not. The percent of preterm birth was higher among mothers with a diagnosis
of asthma when compared to those without (11.5% vs. 9.1% resp.)
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4.2.3

NAA AND ASTHMA
Table 12 displays the results of examining the association between asthma and study

outcomes in the presence of absence of NAA. The percent of LBW and PTB were similarly
distributed across asthma categories in the presence or absence of NAA. The percent of SGA was
lowest among asthmatic women who also had NAA and highest among women who had asthma
only.
The association between asthma and study outcomes when examined across NAA type is
displayed in Tables 32 and 33 (see Appendix F, Tables 32 and 33). In the presence of AR the percent
of LBW among asthmatic mothers was slightly lower than the percent of LBW among non –
asthmatic mothers. This result was not significant.
The percent of SGA is lower among asthmatic mothers with AR and mothers with neither
complaint than it was among non – asthmatic mothers with AR and asthmatic mothers without AR.
This again did not achieve statistical significance.
In the presence of AR, the percent of preterm birth was higher among asthmatic mothers
when compared to non – asthmatic mothers (12.5% vs 8.5% resp.; p < 0.10). The percent of PTB
was lowest among mothers who had AR only and highest among mothers with both disorders.
The percent of LBW was similar across asthma categories (see Appendix F, Table 33). In the
presence of AD the percent of LBW among asthmatic women increases and tended towards being
significantly different from the percent with LBW among mothers with AD only.
A similar pattern was seen with the percent of SGA. In the presence of AD the percent of
SGA among asthmatic and non – asthmatic women was 3.0% and 1.8% resp. However this result
did not achieve statistical significance.
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The percent of preterm birth was similar among mothers with asthma and mothers without
asthma provided mothers had a diagnosis Atopic Dermatitis, although the percent of PTB among
asthmatic mothers was slightly higher (10.1% vs. 9.3%). When there was no diagnosis of Atopic
Dermatitis, the percent of PTB was higher among mothers with asthma compared to mothers
without asthma (11.6% vs. 9.1% resp.).

4.3

MULTIVARIABLE MODELING
Table 13 shows the crude relative risks (RRC) and adjusted relative risks (RRA) from Poisson

regression models predicting an outcome of LBW among infants born after completing at least 37
weeks of gestation. Mothers with NAA had a reduced risk of having an infant with LBW (RR A =
0.96; p > 0.10) when compared to mothers who did not have NAA. While mothers with asthma had
an increased risk of having an infant born LBW (RRA = 1.05; p > 0.10) when compared to mothers
who do not.
Female infants are more likely to be born LBW compared to male infants (RR A = 1.43; p <
0.001). Infants born to BNH mothers are more likely to be born LBW when compared to WNH
mothers (RRA = 2.307; p < 0.001). There was no significant difference in the risk of LBW among
infants born to Hispanic mothers when compared to WNH mothers (RRA = 1.18; p > 0.10). Infants
born to mothers of “other” ethnicity had an increased risk of LBW compared to infants born to
WNH mothers (RRA = 2.712; p = 0.010). Mothers who smoked during pregnancy were more likely
to give birth to LBW infants (RRA = 1.813; p < 0.001) compared to those who did not smoke during
pregnancy.
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Table 14 shows the crude relative risks (RRC) and adjusted relative risks (RRA) from Poisson
regression models predicting an outcome of SGA. Mothers with NAA had a reduced risk of having
an infant who was SGA when compared to mothers without NAA (RRA = 0.94; p > 0.10). While
mothers with asthma had increased risk of having an infant born SGA (RRA = 1.11; p > 0.10) when
compared to those who did not have asthma.
Older mothers were more likely to have infants born SGA (RRA = 1.06; p < 0.10). Infants
born to BNH mothers are more likely to be born SGA when compared to WNH mothers (RRA =
1.85; p < 0.001). There was no significant difference in the risk of SGA among Hispanic mothers
when compared to WNH mothers (RRA = 0.98; p > 0.10). Infants born to mothers of “other
ethnicity” had an increased risk of SGA when compared to WNH mothers (RRA = 2.69; p < 0.10).
Mothers who smoked during pregnancy were more likely to have infants born SGA when compared
to mothers who did not smoke during pregnancy (RRA = 2.09; p < 0.001). Mothers who had pre –
pregnancy hypertension were more likely to have an infant born SGA when compared to mothers
who did not have pre – pregnancy hypertension (RRA = 2.45; p < 0.001).
Table 15 shows the crude relative risks (RRC) and adjusted relative risks (RRA) from Poisson
regression models predicting an outcome of PTB. Mothers with NAA had reduced risk of having a
PTB when compared to mothers without NAA (RRA = 0.95; p > 0.10). While mothers with asthma
had increased risk of having a PTB (RRA = 1.20; p = 0.03) when compared to those who did not
have asthma.
BNH mothers were more likely to have a PTB when compared to WNH mothers (RR A =
1.32; p < 0.001). Hispanic mothers were less likely than WNH mothers to have a PTB (RRA 0.59; p
< 0.05). There was no significant difference in the risk of PTB among mothers of “other” ethnicity
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when compared to WNH mothers (RRA 0.96; p > 0.10). Mothers who had gestational diabetes were
more likely to have a PTB compared to mothers who did not have gestational diabetes (RR A = 1.61;
p < 0.05). Mothers who had pre – pregnancy hypertension were more likely to have a PTB when
compared to mothers who did not have pre – pregnancy hypertension (RRA = 2.68; p < 0.001).

4.4

SUMMARY OF SAMPLE CHARACTERISTICS BY RACE/ETHNICITY
There were 4,607 white non – Hispanic (WNH) women and 4,556 black non – Hispanic

(BNH) women from whom data was further analyzed. Table 16 shows the distribution of NAA
among WNH women and BNH women. Allergic rhinitis (AR) was more prevalent among WNH
women when compared to BNH women (12.4% vs. 10.7%; p < 0.05) while atopic dermatitis (AD)
was more prevalent among BNH women when compared to WNH women (11.1% vs. 8.8%; p <
0.001).
Figure 7 displays the percent of mothers with an atopic disorder by infant birth weight by
maternal race/ethnicity. Non – asthmatic atopy (NAA) displayed a significant increasing trend with
infant birth weight for both WNH and BNH mothers (Figure 7). 11% of WNH mothers and 18%
of BNH mothers who had infants weighing less than 1,000 grams at birth, also had NAA compared
to 20% of those weighing 2,500 grams or more at birth, for both sets of mothers (Figure 7). Appendix
G, Figures 21 and 22 display the percent of mothers with AR and AD respectively by infant birth
weight for both WNH and BNH mothers. Both AR and AD displayed a significant increasing trend
with infant birth weight for both sets of women. While asthma displayed a significant decreasing
trend with birth weight across maternal race/ethnicity. Both WNH and BNH mothers who had
smaller infants at birth had higher percentages with asthma (Figure 8).
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Figure 9 displays the percent of mothers with NAA across infant gestational age at birth by
maternal race/ethnicity. There was a significant increasing trend with infant gestational age at birth
for both WNH and BNH mothers. Mothers with higher percentages of NAA gave birth to infants
with greater gestational ages at birth. 11% of WNH mothers and 16% of BNH mothers whose
infants were born between 24 and 27 weeks of gestation, also had NAA compared with 21% of those
born after completing at least 36 weeks of gestation among both sets of women. Figure 10 displays
the percent of mothers with NAA across fetuses at risk for each gestational age (i.e. fetuses who were
born with a greater gestational age) by maternal race/ethnicity. There is a significant overall
increasing trend as well as a significant increasing trend up to 36 weeks of gestation for both WNH
and BNH mothers. Figure 23 (see Appendix G) displays the percent of mothers with AR across
gestational age at birth by maternal race/ethnicity. There is a significant increasing trend with
gestational age at birth for both WNH and BNH mothers. Mothers with higher percentages of AR
gave birth to infants with greater gestational ages at birth. Figure 24 (see Appendix G) displays with
percentage of mothers with an AR across fetuses at risk for each gestational age by maternal
race/ethnicity. There is a significant overall increasing trend as well as a significant increasing trend
up to 36 weeks of gestation for both WNH and BNH mothers. Figure 25 (see Appendix G) displays
the percent of mothers with AD across gestational age at birth by maternal race/ethnicity. There is
a significant increasing trend with gestational age at birth for WNH mothers, while the trend is
significant but decreasing among BNH mothers. WNH mothers with higher percentages of AD gave
birth to infants with greater gestational ages at birth, while BNH mothers with higher percentages
of AD gave birth to infants with shorter gestational ages at birth. Figure 26 (see Appendix G) displays
the percentage of mothers with AD across fetuses at risk for each gestational age by maternal
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race/ethnicity. There is a significant overall increasing trend as well as a significant increasing trend
up to 36 weeks of gestation for both WNH and BNH mothers. Figure 11 displays the percent of
mothers with asthma across gestational age at birth by maternal race/ethnicity. There is a significant
decreasing trend with gestational age at birth for both WNH and BNH mothers. Mothers who
delivered earlier had higher percentages with asthma. Figure 12 displays with percentage of mothers
with asthma across fetuses at risk for each gestational age by maternal race/ethnicity. There is a
significant overall increasing trend as well as a significant increasing trend up to 36 weeks of gestation
for both WNH and BNH mothers.
Primiparous WNH mothers were slightly older than BNH mothers (see Appendix F, Table
34). Infants born to primiparous WNH mothers tended to have a greater gestational age at birth
and birth weight compared to infants born to primiparous BNH (see Appendix F, Table 34). The
percent of mothers who smoked both prior to (32.1% vs. 8.7%; p < 0.001) and during (25.0% vs.
6.0%) pregnancy was much higher among WNH women when compared to BNH women (see
Appendix F, Table 35). The percent of mothers who had pre – pregnancy diabetes (0.5% vs. 0.9%;
p < 0.05), and pre–pregnancy hypertension (1.4% vs. 2.8%; p < 0.001) were lower among WNH
women compared to BNH women (see Appendix F, Table 35). While gestational diabetes was
slightly lower among WNH, the percent with same among BNH was comparable (3.0% vs. 3.6%; p
< 0.10).
Across both ethnicities, comparing mothers with NAA to mothers without NAA did not
display significant results for age and gestational age at birth (see Appendix F, Table 36). WNH
mothers with NAA gave birth to heavier infants when compared to WNH mothers without NAA (p
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< 0.10). There was no difference in the birth weights of infants born to BNH mothers with or
without NAA.
Study outcomes were all disproportionately distributed across maternal race/ethnicity (Table
17). The percent of infants born LBW among infants born to BNH mothers was twice that of the
percent of same born to WNH mothers (6.0% vs. 3.0%; p < 0.001). A Similar trend in SGA was
seen (2.5% vs. 1.6%; p < 0.001) and PTB (11.3% vs. 8.4%; p < 0.001).
The percent of WNH mothers with NAA who had pre – pregnancy hypertension was higher
than the percent of WNH others without NAA who had pre – pregnancy hypertension (2.0% vs.
1.2%; p < 0.10) (see Appendix F, Table 37). The distributions of other characteristics were similar
across NAA category for both ethnicities (see Appendix F, Table 37).

4.5

SUMMARY OF CHARACTERISTCS BY ATOPY TYPE BY RACE/ETHNICITY

4.5.1

ASTHMA
The prevalence of asthma was lower among WNH women when compared to BNH

women (14.9% vs. 17.5%; p < 0.05; Appendix F, Table 35). The prevalence of asthma however,
was comparable when comparing mothers with and without NAA for each race/ethnicity (see
Appendix F, Table 37). Study outcomes did not differ across NAA category for mothers of either
race/ethnicity (Table 18).
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4.5.2

NAA AND ASTHMA
Table 19 shows the results of examining the interaction of asthma and NAA more closely

among WNH women and its effect on study outcomes.
The percent of infants born LBW was elevated among WNH women with asthma compared
those without asthma (3.9% and 2.8%; Table 19). Once asthma was excluded, the remaining WNH
mothers with NAA had lower, albeit slightly lower, percentages of infants born LBW (2.6% and
2.9%; Table 19). However, in the presence of asthma, NAA appears to exacerbate the risk of LBW.
The percent of infants born LBW was 4.4% and 3.9% (Table 19) among WNH asthmatic women
with and without AD respectively.
This trend was also present for SGA among WNH mothers (Table 19). The percent of
infants born SGA to WNH mothers who had asthma was slightly higher than that among WNH
mothers who did not have asthma (2.3% vs. 1.5%; p < 0.10). Again, if asthma were excluded the
remaining WNH mothers with NAA had slightly lower percentages of infants born SGA (1.3% and
1.5% respectively among non – asthmatics with and without NAA). However once asthma was
present, the percent of infants born SGA appeared to be increased if the mother also had NAA. The
percent of infants born SGA was 2.2% among WNH mothers with asthma only and 3.2% among
WNH who had asthma along with NAA.
The percent of PTB was slightly higher among WNH mothers who had asthma when
compared to those who did not (10.1% vs. 8.1%; p < 0.10) (Table 19). Among those who did not
have asthma, those with NAA had a lower percent of PTB, 7.3% and 8.3% respectively among non
– asthmatics with and without NAA. Once asthma was present NAA did not affect the percent of
PTB.
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The asthma and NAA interaction appeared to have a different effect among BNH mothers
(Table 20). For each study outcome the highest percentages occurred among BNH women with
asthma only.
The percent of infants born LBW was similar among BNH mothers with or without asthma
(5.9% and 6.0%; Table 20). However, asthmatic mothers appeared to receive protection against
LBW if they also had NAA. The percent of infants born LBW among asthmatics was lower if the
mother also had NAA, 4.8% and 6.2% respectively among BNH asthmatic women with and without
NAA. In the absence of asthma the protection provided by NAA was slight. The percent of infants
born LBW among non – asthmatic women was 5.8% and 6.1% respectively for those with NAA and
those without.
The percent of infants born SGA was similar among BNH mothers with or without asthma
(2.5%; Table 20). And further among those without asthma there was no variation in the percent of
PTB with or without NAA. However among those with asthma there was a lower percent of infants
born SGA among those with NAA compared to those without, 0.6% and 3.0% respectively for
asthmatic BNH women with and without NAA.
There was a higher percent of PTB among BNH women with asthma compared to those
without (13.0% and 11.0%; Table 20). While NAA did not affect the percent of PTB among non –
asthmatics, it appeared to protect asthmatic women from PTB. The percent of PTB among BNH
asthmatic mothers was 12.1% and 13.2% respectively among those with NAA and those without.
Looking more closely at the interaction between asthma and type of NAA by race/ethnicity
continued to reveal some variations. Table 38 (see Appendix F) shows the distributions of study
outcomes and the interaction of asthma and AR among WNH women.
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In the absence of asthma, WNH women with AR had lower percentages of infants born
LBW compared to those without AR i.e. those with no atopy (2.5% and 2.8%; see Appendix F,
Table 38). However, once asthma was present the percent of infants born LBW was higher (4.4%)
among mothers who also had AR compared to those with asthma only (3.8%).
This trend was also present for SGA among WNH mothers. The percent of infants born
SGA among WNH mothers who had asthma was slightly higher than that among WNH mothers
who did not have asthma (2.3% vs. 1.5%; p < 0.10; see Appendix F, Table 38). The percent of infants
born SGA was slightly lower among non – asthmatic WNH mothers with AR compared to those
without AR i.e. those with no atopy (1.3% and 1.5%). When asthma was present, the percent of
infants born SGA appeared to be increased if the mother also had AR. The percent of SGA was
2.2% among WNH mothers with asthma only and 3.0% among WNH who had both asthma and
AR.
AR did appear to reduce the percent of PTB among both asthmatic and non – asthmatic
WNH women (see Appendix F, Table 38). The percent of PTB among WNH asthmatic women was
9.9% and 10.1% respectively for those with and without AR. While the percent of PTB was 7.6%
and 8.2% respectively among non – asthmatic with and without AR.
AR in the presence of asthma appeared to have a different effect among BNH mothers (see
Appendix F, Table 39). The percent of infants born LBW was similar among BNH mothers with or
without asthma (5.9% and 6.0%). Among BNH mothers with asthma, the percent of infants born
LBW was lower among those with AR compared to those without AR (2.9% and 6.4%). However
the percent of infants born LBW appeared was greater among non – asthmatic women with AR
compared to those no atopy (6.9% and 5.9%).
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The percent of infants born SGA was similar among BNH mothers with or without asthma
(2.5%; see Appendix F, Table 39). However the percent of infants born SGA was lowest among
asthmatic BNH mothers who had AR (0.6%) and this percent was lower than that among asthmatic
BNH mothers without AR (2.8%). The highest percent of infants born SGA was among non –
asthmatic BNH women with AR (3.5%) and this percent was higher than among BNH with no
atopy (2.4%).
The percent of PTB among BNH mothers with asthma appeared to be made worse by the
presence of AR (see Appendix F, Table 39). The percent of PTB was 15.0% and 12.6% respectively
among BNH asthmatic women with and without AR. Once asthma was excluded, the remaining
BNH mothers had lower percentages of PTB if they also had AR compared to those who had no
atopy (10.1% and 11.1%).
Examining how the interaction between asthma and atopic dermatitis (AD) affects study
outcomes among WNH mothers is shown in Table 40 (see Appendix F).
The percent of infants born LBW was higher among WNH mothers who asthma compared
to those who did not (see Appendix F, Table 40). AD appeared to exacerbate the effect of asthma
on the percent of infants born LBW. Among asthmatic women, 10.0% and 3.6% had infants born
LBW among those with AD and those without AD respectively. Again once asthma was excluded,
there was slightly lower percent of infants born LBW among mother with AD compared to among
those with no atopy (2.6% and 2.8% respectively).
A similar exacerbating trend was observed for infants born SGA among WNH women (see
Appendix F, Table 40). The percent of infants born SGA was higher among asthmatic WNH with
AD compared to those without AD (9.1% and 2.0% respectively). Again, once asthma was excluded,
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WNH mothers with AD only had slightly lower percentages of infants born SGA compared to
mothers with no atopy (1.3% and 1.5%, respectively)
The lowest percent of PTB among WNH mothers, was among those without asthma but
with AD (7.0%) this compared to those no atopy (8.2%). And among asthmatic WNH mothers
those with AD had a lower percent of PTB compared to those without (9.1% and 10.1%
respectively).
Examining how the interaction between asthma and AD affects study outcomes among BNH
mothers is shown in Table 41 (see Appendix F).
AD appears to exacerbate the effect that asthma had on LBW among BNH mothers. The
percent of infants born LBW is 9.1% and 5.6% among asthmatics with and without AD respectively.
However it appears that once asthma is excluded AD is protective against LBW. The percent of
infants born LBW is 5.3% and 6.1% among non – asthmatics with AD and those with no atopy
respectively.
While there was no difference between the percent of BNH mothers who had infants born
SGA among those with asthma and those without asthma, AD appears to protect against SGA (see
Appendix F, Table 41). The percentages of infants born SGA were lower among mothers who had
AD (0% and 2.0% respectively among asthmatics and non – asthmatics) when compared to the
percentages among mothers who did not have AD (2.7% and 2.6% respectively for asthmatics and
non – asthmatics).
The highest percent of PTB occurred among BNH mothers who had asthma only (13.2%)
compared to those who had both asthma and AD (10.0%; see Appendix F, Table 41). However,
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when asthma was not present, BNH women with AD had higher percentages with PTB compared
to those without (11.7% and 10.9% respectively for non – asthmatics with and without AD).

4.6

MULTIVARIABLE MODELING BY RACE/ETHNICITY
Table 21 shows the crude relative risks (RRC) and adjusted relative risks (RRA) from separate

Poisson regression models predicting an outcome of LBW among infants born after completing at
least 37 weeks of gestation to WNH and BNH mothers. Mothers with NAA had a reduced risk of
having an infant born LBW compared to those without NAA (RR A = 0.95 and 0.94 for WNH and
BNH resp.; p > 0.10). While WNH mothers with asthma had an increased risk of having an infant
born LBW (RRA = 1.29; p > 0.10) and BNH mothers with asthma had a reduced risk of having an
infant born LBW (RRA = 0.96; p > 0.10); compared to those without asthma.
Female infants born to BNH mothers were more likely to be born LBW compared to male
infants (RRA = 1.66; p < 0.001). While smoking during pregnancy increased the risk of infants being
born LBW among WNH mothers (RRA = 2.03; p < 0.001).
Table 22 shows the crude relative risks (RRC) and adjusted relative risks (RRA) from separate
Poisson regression models predicting an outcome of SGA among infants born to WNH and BNH
mothers. Mothers with NAA had a reduced risk of having an infant born SGA compared to those
without NAA (RRA = 0.97 and 0.84 for WNH and BNH resp.; p > 0.10). While WNH mothers with
asthma had an increased risk of having an infant born SGA (RRA = 1.47; p > 0.10) and BNH mothers
with asthma had a reduced risk of having an infant born SGA (RRA = 0.96; p > 0.10); compared to
those without asthma.
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Female infants born to WNH mothers were less likely to be born SGA compared to male
infants (RRA = 0.51; p < 0.05). While increased age increased the risk of infants being born SGA
among BNH mothers (RRA = 1.10; p < 0.10). Smoking during pregnancy increased the risk of infants
being born SGA among WNH mothers (RRA = 2.22; p < 0.05). Pre – pregnancy hypertension
increased the risk of infants being born SGA for both WNH and BNH mothers (RR A = 4.09 and
2.03 resp.; p < 0.05 and p < 0.10 resp.).
Table 23 shows the crude relative risks (RRC) and adjusted relative risks (RRA) from separate
Poisson regression models predicting an outcome of PTB among infants born to WNH and BNH
mothers. WNH mothers with NAA had a reduced risk of PTB, while BNH mothers with NAA had
an equal risk of PTB compared to those without (RRA = 0.90 and 1.00 for WNH and BNH resp.; p
> 0.10). While both WNH and BNH mothers with asthma had an increased risk of PTB (RR A =
1.20 and 1.17 resp.; p > 0.10).
BNH mothers with gestational diabetes were more likely than those without to have a PTB
(RRA = 1.76; p < 0.05). Both WNH and BNH with pre – pregnancy hypertension were more likely
to have a PTB than those without (RRA = 3.81 and 2.22 resp.; p < 0.001).

4.7

SELECTED CONTROLS VS. REMAINING CONTROLS
There were a total of 63,657 potential controls. 7,972 were selected as controls (SC) and

matched to mothers with NAA according to their ages, sexes of infants born and asthma diagnoses.
The other 55,685 were the remaining controls (RC). Controls who were selected were slightly
younger than controls who were not selected (mean = 20.8 vs. 21.2 yrs.; p < 0.001) (see Appendix F,
Table 42). This would be expected as SC were matched to NAA diagnosed mothers on age. The
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birth weights of infants born to SC were slightly lower than those of infants born to RC (mean =
3,151.2 vs. 3,164.5g; p < 0.10). The sex of infants was similarly distributed across SC and RC.
Maternal race/ethnicity was distributed differently among SC and RC (Table 24). The proportion
of WNH mothers among controls selected was comparable to the proportion of BNH mothers
among selected. While, among the controls who were not selected, there was a slightly higher
proportion of WNH mothers compared to BNH mothers (Table 24). The percent of SC with asthma
was much higher the percent of RC with asthma (Table 24). This would be expected as SC controls
were also matched to NAA diagnosed women on asthma diagnosis. The percentages of SC who
smoked prior to and during pregnancy were similar to the percentages of RC who smoked prior to
and during pregnancy. The percent of SC with pre – pregnancy hypertension was slightly higher
than the percent of RC with pre – pregnancy hypertension (2.0% vs. 1.7% resp.; p < 05).
The percentages of all study outcomes; low birth weight, small for gestational age and
preterm birth were similarly distributed among controls who were selected when compared to those
who were not selected (Table 25).

4.8

CHAPTER FOUR TABLES AND FIGURES

Table 7: Summary of Atopy
Exposure

N (%)

Non – Asthmatic Atopy

1,993 (20.0)

Allergic Rhinitis (AR)

1,093 (11.0)

Atopic Dermatitis (AD)

959 (9.6)
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Table 8: Summary of Study Outcomes (N = 9,965)
Characteristic
n (%)
a

394 (4.4)

Low birth weight

Small for gestational age

b

Birth weight (grams)
Extremely lbw (< 1,000)
Very lbw (1,000 – 1,499)
Moderately lbw (1,500 – 2,499)
Normal bw (2,500 – 3,999)
High bw (4,000+)

202 (2.0)

57 (0.6)
92 (0.9)
861 (8.7)
8,468 (85.0)
481 (4.8)

Preterm birth
Gestational age at birth (weeks)
Extremely preterm (< 28)
Very preterm (28 – < 32)
Moderately preterm (32 – <37)
Term (37+)

944 (9.5)
55 (0.6)
94 (1.0)
795 (8.0)
9,003 (90.5)

a

For infants born after completing 37 weeks of gestation, N = 9,017;

b

Birth weight less than 2 standard deviations from the sex – and gestational age – specific mean
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Table 9: Study Outcomes by Atopy Category
Characteristic

Low birth weighta
Yes
Small for gestational ageb
Yes
Birth weight (grams)
Extremely LBW (< 1,000)
Very LBW (1,000 – 1,499)
Moderately LBW (1,500 – 2,499)
Normal (2,500 – 3,999)
High (4,000+)
Preterm birth
Yes
Gestational age at birth (weeks)
Extremely preterm (< 28)
Very preterm (28 – < 32)
Moderately preterm (32 – <37)
Term (37+)
*p < 0.10; **p < 0.05; ***p < 0.001

Non–Asthmatic Atopy
Present/Cases
Absent/Controls
(N = 1,993)
(N = 7,972)

Asthma
Present
(N = 1,545)

Absent
(N = 8,420)

4.3%

4.3%

4.4%

4.9%

2.0%

2.1%

2.4%

2.0%
**

0.5%
0.7%
8.9%
85.2%
5.2%

0.6%
1.0%
8.7%
85.0%
4.8%

0.6%
1.4%
10.0%
84.0%
4.0%

0.6%
0.8%
8.4%
85.2%
5.0%
**

9.3%

9.5%

11.5%

9.1%
***

0.4%
1.0%
7.9%
90.7%

0.6%
0.9%
8.0%
90.5%

a

0.3%
1.5%
9.7%
88.5%

0.6%
0.8%
7.8%
90.9%

For infants born after completing 37 weeks of gestation; N = 1,807 and 7,210 for NAA present and absent respectively; N = 1,367 and
7,650 for asthma present and absent respectively
b
Birth weight less than 2 standard deviations from the sex – and gestational age – specific mean
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Table 10: Maternal Characteristics across NAA type
a
Characteristic
Allergic Rhinits
Present
(N = 1,093)
Asthma
Yes

21.2%

Mother’s race
White non – Hispanic
Black non – Hispanic
Hispanic
Other

52.3%
44.7%
2.6%
0.4%

Absent
(N = 8,872)

a

Atopic Dermatitis
Present
Absent
(N = 959)
(N = 9,006)

***

***
14.8%

10.4%

45.5%
45.9%
7.6%
1.1%

42.4%
52.9%
4.0%
0.7%

***

16.1%
***
46.7%
45.0%
7.3%
1.0%

a

Each condition was considered separately
*p < 0.10; **p < 0.05; ***p < 0.001

Table 11: Study Outcomes across NAA Type
a
Characteristic
Allergic Rhinits

b

Low birth weight
SGA

c

Preterm birth

a

Atopic Dermatitis
Present
Absent
(N = 959)
(N = 9,006)

Present
(N = 1,093)

Absent
(N = 8,872)

4.4%

4.6%

4.4%

4.4%

2.3%

2.0%

1.9%

2.0%

9.3%

9.5%

9.4%

9.5%

a

Each condition was considered separately

b

For infants born after completing 37 weeks of gestation; N = 991 and 8,026 for AR present and
absent respectively; N = 869 and 8,148 for AD present and absent respectively
c
Birth weight less than 2 standard deviations from the sex – and gestational age – specific mean
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Table 12: Study Outcomes by Atopy Types and Combinations
Outcome

PTB

NAA Present
Asthma
No Asthma

NAA Absent
Asthma
No Asthma

(N = 1,545)

(N = 8,420)

(N = 309)

(N = 1,684)

(N = 1,236)

(N = 6,736)

a

4.9%

4.3%

4.7%

4.2%

4.9%

4.3%

b

2.4%

2.0%

1.6%

2.0%

2.6%

2.0%

11.5%

9.1% **

11.4%

9.0%

11.6%

9.2% **

LBW
SGA

Asthma
Present
Absent

a

For infants born after completing 37 weeks of gestation; N = 1,367 and 7,650 for Asthma present
and absent respectively; N = 274 and 1,533 for Asthma present and absent respectively among
mothers with NAA; N = 1,093 and 6,117 for Asthma present and absent respectively among
mothers without NAA.
b
Birth weight less than 2 standard deviations from the sex – and gestational age – specific mean
*p < 0.10; **p < 0.05; ***p < 0.001
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Table 13: Poisson Regression Models Displaying the Crude Relative Risk (RRC) and Adjusted
Relative Risk (RRA) of Low Birth Weight among infants born after completing 37 weeks of
gestation (N = 9,017)
Outcome – LBW

RRC (95% CI)

a

RRA (95% CI)

a

NAA
No
Yes

1.00 [reference]
0.97 (0.75 – 1.24)

1.00 [reference]
0.96 (0.75 – 1.23)

No
Yes

1.00 [reference]
1.15 (0.88 – 1.45)

1.00 [reference]
1.05 (0.80 – 1.36)

1.00 [reference]
1.43 (1.17 – 1.74) ***

1.00 [reference]
1.43 (1.17 – 1.74) ***

1.00 (0.95 – 1.06)

1.01 (0.96 – 1.07)

Asthma

Infant sex
Male
Female
Mother's age

Race/Ethnicity
WNH
1.00 [reference]
1.00 [reference]
BNH
2.02 (1.63 – 2.51) ***
2.31 (1.84 – 2.90) ***
HISP
1.02 (0.63 – 1.63
1.18 (0.73 – 1.91)
OTHER
2.57 (1.20 – 2.50) **
2.71 (1.26 – 5.82) **
Smoked during pregnancy
No
1.00 [reference]
1.00 [reference]
Yes
1.35 (1.05 – 1.74) **
1.82 (1.39 – 2.37) ***
Gestational diabetes
No
1.00 [reference]
1.00 [reference]
Yes
0.91 (0.50 – 1.66)
0.85 (0.47 – 1.56)
Pre–pregnancy hypertension
No
1.00 [reference]
1.00 [reference]
Yes
1.58 (0.84 – 2.96)
1.37 (0.73 – 2.57)
* p < 0.10; ** p < 0.05; *** p < 0.001
a
95% Confidence Interval
In a model adjusting for other predictors RRA & 95% confidence interval for the NAA – Asthma
interaction 1.02 (0.53 – 1.99)
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Table 14: Poisson Regression Models Displaying the Crude Relative Risk (RRC) and Adjusted
Relative Risk (RRA) of Small for Gestational Age (N = 9,965)
Outcome – SGA

RRC (95% CI)

a

RRA (95% CI)

a

NAA
No
Yes

1.00 [reference]
0.97 (0.67 – 1.36)

1.00 [reference]
0.94 (0.66 – 1.34)

1.00 [reference]
1.22 (0.85 – 1.74)

1.00 [reference]
1.11 (0.78 – 1.59)

1.00 [reference]
0.94 (0.72 – 1.25)

1.00 [reference]
0.95 (0.72 – 1.25)

1.07 (0.99 – 1.15) *

1.06 (0.99 – 1.15) *

Asthma
No
Yes
Infant sex
Male
Female
Mother's age

Race/Ethnicity
WNH
1.00 [reference]
1.00 [reference]
BNH
1.57 (1.17 – 2.10) **
1.85 (1.35 – 2.52) ***
HISP
0.80 (0.40 – 1.61)
0.98 (0.48 – 1.97)
OTHER
2.49 (0.91 – 6.81) *
2.69 (0.98 – 7.39) *
Smoked during pregnancy
No
1.00 [reference]
1.00 [reference]
Yes
1.71 (1.22 – 2.37) **
2.09 (1.47 – 2.97) ***
Gestational diabetes
No
1.00 [reference]
1.00 [reference]
Yes
1.21 (0.60 – 2.45)
1.04 (0.51 – 2.13)
Pre–pregnancy hypertension
No
1.00 [reference]
1.00 [reference]
Yes
2.79 (1.52 – 5.13) **
2.45 (1.32 – 4.53) **
* p < 0.10; ** p < 0.05; *** p < 0.001
a
95% Confidence Interval
In a model adjusting for other predictors RRA & 95% confidence interval for the NAA – Asthma
interaction 0.63 (0.23 – 1.76)
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Table 15: Poisson Regression Models Displaying the Crude Relative Risk (RRC) and Adjusted
Relative Risk (RRA) of Preterm Birth (N = 9,965)
RRC (95% CI)

Outcome – PTB

a

RRA (95% CI)

a

NAA
No
Yes

1.00 [reference]
0.98 (0.84 – 1.15)

1.00 [reference]
0.95 (0.81 – 1.12)

No
Yes

1.00 [reference]
1.26 (1.07 – 1.49) **

1.00 [reference]
1.20 (1.02 – 1.41) **

1.00 [reference]
0.98 (0.86 – 1.11)

1.00 [reference]
0.97 (0.85 – 1.10)

1.01 (0.98 – 1.05)

1.00 (0.97 – 1.04)

Asthma

Infant sex
Male
Female
Mother's age
Race/Ethnicity
WNH
1.00 [reference]
BNH
1.35 (1.18 – 1.54) ***
HISP
0.58 (0.41 – 0.82) **
OTHER
0.95 (0.47 – 1.92)

1.00 [reference]
1.32 (1.15 – 1.51) ***
0.59 (0.41 – 0.84) **
0.96 (0.48 – 1.94)

Smoked during pregnancy
No
Yes

1.00 [reference]
0.98 (0.81 – 1.17)

1.00 [reference]
1.04 (0.86 – 1.25)

No
Yes

1.00 [reference]
1.74 (1.32 – 2.29) ***

1.00 [reference]
1.61 (1.22 – 2.13) **

Gestational diabetes

Pre–pregnancy hypertension
No
1.00 [reference]
1.00 [reference]
Yes
3.00 (2.28 – 3.94) *** 2.68 (2.03 – 3.53) ***
* p < 0.10; ** p < 0.05; *** p < 0.001
a
95% Confidence Interval
In a model adjusting for other predictors RRA & 95% confidence interval for the NAA – Asthma
interaction 0.98 (0.65 – 1.48)
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Table 16: Summary of Atopy by Maternal Race/Ethnicity
WNH
(N = 4,607)
Exposure
n (%)

BNH
(N = 4,556)
n (%)

Non – Asthmatic Atopy

960 (20.8)

957 (21.0)

Allergic Rhinitis (AR) **

572 (12.4)

489 (10.7)

407 (8.8)

507 (11.1)

Atopic Dermatitis (AD) ***
*p < 0.10; **p < 0.05; ***p < 0.001

Table 17: Summary of Study Outcomes by Maternal Race/Ethnicity
Characteristic
WNH (N = 4,607) BNH (N = 4,556)
n (%)
n (%)
a

125 (3.0)

242 (6.0)

74 (1.6)

115 (2.5)

18 (0.4)
38 (0.8)
288 (6.3)
3,966 (86.1)
297 (6.5)

39 (0.9)
53 (1.2)
527 (11.6)
3,803 (83.5)
134 (2.9)

387 (8.4)

515 (11.3)

18 (0.4)
35 (0.8)
334 (7.3)
4,220 (91.6)

37 (0.8)
55 (1.2)
423 (9.3)
4,041 (88.7)

Low birth weight ***
b

Small for gestational age **
Birth weight (grams) ***
Extremely lbw (< 1,000)
Very lbw (1,000 – 1,499)
Moderately lbw (1,500 – 2,499)
Normal bw (2,500 – 3,999)
High bw (4,000+)
Preterm birth ***
Gestational age at birth (weeks) ***
Extremely preterm (< 28)
Very preterm (28 – < 32)
Moderately preterm (32 – <37)
Term (37+)
a

For infants born after completing 37 weeks of gestation; N = 4,220 and 4,041 respectively

b

Birth weight less than 2 standard deviations from the sex– and gestational age–specific mean
*p < 0.10; **p < 0.05; ***p < 0.001
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Table 18: Study Outcomes by NAA by Maternal Race/Ethnicity
Characteristic
WNH
NAA+
NAA–
(N = 960)
(N = 3,647)
a

BNH
NAA+
(N = 957)

NAA–
(N = 3,599)

2.8%

3.0%

5.7%

6.1%

1.6%

1.6%

2.2%

2.6%

Birth weight (grams)
Extremely lbw (< 1,000)
Very lbw (1,000 – 1,499)
Moderately lbw (1,500 – 2,499)
Normal bw (2,500 – 3,999)
High bw (4,000+)

0.2%
0.4%
6.2%
86.6%
6.7%

0.4%
0.9%
6.3%
86.0%
6.4%

0.7%
0.9%
11.1%
83.8%
3.5%

0.9%
1.2%
11.7%
83.4%
2.8%

Preterm birth

7.7%

8.6%

11.3%

11.3%

Gestational age at birth (weeks)
Extremely preterm (< 28)
Very preterm (28 – < 32)
Moderately preterm (32 – <37)
Term (37+)

0.2%
0.7%
6.8%
92.3%

0.4%
0.8%
7.4%
91.4%

0.6%
1.4%
9.3%
88.7%

0.9%
1.2%
9.3%
88.7%

Low birth weight

Small for gestational age

b

a

For infants born after completing 37 weeks of gestation; N = 886 and 3,334 for NAA present and
absent respectively among WNH. N = 849 and 3,192 for NAA present and absent respectively
among BNH.
b
Birth weight less than 2 standard deviations from the sex– and gestational age–specific mean
*p < 0.10; **p < 0.05; ***p < 0.001
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Table 19: Study Outcomes by Atopy Types and Combinations among WNH women
Outcome
Asthma
NAA Present
NAA Absent
Present
Absent
Asthma
No Asthma
Asthma
No Asthma
(N = 684)

(N = 3,923)

(N = 127)

(N = 833)

(N = 557)

(N = 3,090)

a

3.9%

2.8%

4.4%

2.6%

3.8%

2.9%

b

2.3%

1.5% *

3.2%

1.3%

2.2%

1.5%

10.1%

8.1% *

10.2%

7.3%

10.1%

8.3%

LBW
SGA
PTB
a

For infants born after completing 37 weeks of gestation; N = 615 and 3,605 for Asthma present
and absent respectively; N = 114 and 772 for Asthma present and absent respectively among
mothers with NAA; N = 501 and 2,833 for Asthma present and absent respectively among
mothers without NAA.
b
Birth weight less than 2 standard deviations from the sex– and gestational age–specific mean
*p < 0.10; **p < 0.05; ***p < 0.001

Table 20: Study Outcomes by Atopy Types and Combinations among BNH women
Outcome
Asthma
NAA Present
NAA Absent
Present
Absent
Asthma
No Asthma
Asthma
No Asthma
(N = 796)

(N = 3,760)

(N = 166)

(N = 791)

(N = 630)

(N = 2,969)

LBWa

5.9%

6.0%

4.8%

5.8%

6.2%

6.1%

b

2.5%

2.5%

0.6%

2.5%

3.0%

2.5%

13.0%

11.0%

12.1%

11.1%

13.2%

11.0%

SGA
PTB
a

For infants born after completing 37 weeks of gestation; N = 693 and 3,348 for Asthma present
and absent respectively; N = 146 and 703 for Asthma present and absent respectively among
mothers with NAA; N = 547 and 2,645 for Asthma present and absent respectively among
mothers without NAA.
b
Birth weight less than 2 standard deviations from the sex– and gestational age–specific mean
*p < 0.10; **p < 0.05; ***p < 0.001
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Table 21: Poisson Regression Models Displaying the Crude Relative Risk (RRC) and Adjusted Relative Risk (RRA) of Low Birth Weight
among infants born after completing 37 weeks of gestation for WNH women (N = 4,220) and BNH women (N = 4,046)
Outcome – LBW

WNH
RRC (95% CI)

a

BNH
RRA (95% CI)

a

RRC (95% CI)

a

RRA (95% CI)

a

NAA
No
Yes
Asthma
No
Yes
Infant sex
Male
Female

1.00 [reference]
0.94 (0.61 – 1.46)

1.00 [reference]
0.95 (0.61 – 1.48)

1.00 [reference]
0.93 (0.68 – 1.28)

1.00 [reference]
0.94 (0.68 – 1.28)

1.00 [reference]
1.39 (0.89 – 2.17)

1.00 [reference]
1.29 (0.83 – 2.02)

1.00 [reference]
0.99 (0.70 – 1.38)

1.00 [reference]
0.96 (0.68 – 1.34)

1.00 [reference]
1.02 (0.72 – 1.45)

1.00 [reference]
1.01 (0.71 – 1.44)

Mother's age
0.99 (0.89 – 1.09)
0.99 (0.90 – 1.09)
Smoked during pregnancy
No
1.00 [reference]
1.00 [reference]
Yes
2.07 (1.45 – 2.96) *** 2.03 (1.42 – 2.90) ***
Gestational diabetes
No
1.00 [reference]
1.00 [reference]
Yes
0.56 (0.14 – 2.27)
0.55 (0.13 – 2.23)
Pre–pregnancy hypertension
No
1.00 [reference]
1.00 [reference]
Yes
1.58 (0.39 – 6.39)
1.69 (0.41 – 6.86)

1.00 [reference]
1.00 [reference]
1.66 (1.28 – 2.15) *** 1.66 (1.28 – 2.16) ***
1.00 (0.93 – 1.08)

1.00 (0.94 – 1.08)

1.00 [reference]
1.35 (0.85 – 2.16)

1.00 [reference]
1.36 (0.85 – 2.17)

1.00 [reference]
1.00 (0.50 – 2.03)

1.00 [reference]
1.00 (0.49 – 2.02)

1.00 [reference]
1.40 (0.69 – 2.84)

1.00 [reference]
1.38 (0.68 – 2.80)

* p < 0.10; ** p < 0.05; *** p < 0.001
a

95% Confidence Interval
In a model adjusting for other predictors RRA for NAA–Asthma interaction among WNH 1.40 (0.46 – 4.21)
In a model adjusting for other predictors RRA for NAA–Asthma interaction among BNH 0.79 (0.33 – 1.91)
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Table 22: Poisson Regression Models Displaying the Crude Relative Risk (RRC) and Adjusted Relative Risk (RRA) of Small for
Gestational Age among WNH women (N = 4,607) and BNH women (4556)
Outcome – SGA

WNH
RRC (95% CI)

a

BNH
RRA (95% CI)

a

RRC (95% CI)

a

RRA (95% CI)

a

NAA
No
Yes
Asthma
No
Yes
Infant sex
Male
Female

1.00 [reference]
0.97 (0.55 – 1.70)

1.00 [reference]
0.97 (0.55 – 1.72)

1.00 [reference]
0.84 (0.52 – 1.35)

1.00 [reference]
0.84 (0.52 – 1.35)

1.00 [reference]
1.58 (0.91 – 2.75)

1.00 [reference]
1.47 (0.84 – 2.57)

1.00 [reference]
0.99 (0.61 – 1.61)

1.00 [reference]
0.96 (0.60 – 1.56)

1.00 [reference]
0.52 (0.32 – 0.85) **

1.00 [reference]
0.51 (0.32 – 0.84) **

1.00 [reference]
1.26 (0.88 – 1.83)

1.00 [reference]
1.28 (0.89 – 1.86)

Mother's age
1.01 (0.89 – 1.14)
0.99 (0.88 – 1.13)
1.11 (1.00 – 1.22) ** 1.10 (0.99 – 1.21) *
Smoked during pregnancy
No
1.00 [reference]
1.00 [reference]
1.00 [reference]
1.00 [reference]
Yes
2.28 (1.44 – 3.62) *** 2.22 (1.40 – 3.52) **
1.66 (0.89 – 3.08)
1.61 (0.86 – 2.99)
Gestational diabetes
No
1.00 [reference]
1.00 [reference]
1.00 [reference]
1.00 [reference]
Yes
0.45 (0.06 – 3.22)
0.38 (0.05 – 2.73)
1.71 (0.80 – 3.68)
1.53 (0.71 – 3.32)
Pre–pregnancy hypertension
No
1.00 [reference]
1.00 [reference]
1.00 [reference]
1.00 [reference]
Yes
4.06 (1.48 – 11.11) ** 4.09 (1.47 – 11.34) ** 2.24 (1.04 – 4.81) ** 2.03 (0.94 – 4.39) *

* p < 0.10; ** p < 0.05; *** p < 0.001
a

95% Confidence Interval
In a model adjusting for other predictors RRA for NAA–Asthma interaction among WNH women 1.87 (0.50 – 6.93)
In a model adjusting for other predictors RRA for NAA–Asthma interaction among BNH women 0.19 (0.02 – 1.54)
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Table 23: Poisson Regression Models Displaying the Crude Relative Risk (RRC) and Adjusted Relative Risk (RRA) of Preterm Birth
among WNH women (N = 4,607) and BNH women (4,556)
Outcome – PTB

WNH
RRC (95% CI)

a

BNH
RRA (95% CI)

a

RRC (95% CI)

a

RRA (95% CI)

a

NAA
No
Yes
Asthma
No
Yes
Infant sex
Male
Female

1.00 [reference]
0.90 (0.70 – 1.16)

1.00 [reference]
0.90 (0.68 – 1.13)

1.00 [reference]
1.00 (0.81 – 1.23)

1.00 [reference]
1.00 (0.81 – 1.24)

1.00 [reference]
1.24 (0.96 – 1.61) *

1.00 [reference]
1.20 (0.92 – 1.56)

1.00 [reference]
1.18 (0.95 – 1.46)

1.00 [reference]
1.17 (0.94 – 1.45)

1.00 [reference]
0.87 (0.71 – 1.06)

1.00 [reference]
0.87 (0.71 – 1.06)

1.00 [reference]
1.07 (0.90 – 1.28)

1.00 [reference]
1.07 (0.90 – 1.27)

Mother's age
1.04 (0.98 – 1.09)
1.02 (0.97 – 1.08)
1.01 (0.96 – 1.06)
1.00 (0.95 – 1.05)
Smoked during pregnancy
No
1.00 [reference]
1.00 [reference]
1.00 [reference]
1.00 [reference]
Yes
1.03 (0.82 – 1.30)
1.01 (0.80 – 1.27)
1.14 (0.81 – 1.61)
1.11 (0.79 – 1.56)
Gestational diabetes
No
1.00 [reference]
1.00 [reference]
1.00 [reference]
1.00 [reference]
Yes
1.59 (0.99 – 2.55) *
1.36 (0.84 – 2.21)
1.81 (1.27 – 2.57) ** 1.76 (1.24 – 2.52) **
Pre–pregnancy hypertension
No
1.00 [reference]
1.00 [reference]
1.00 [reference]
1.00 [reference]
Yes
4.07 (2.62 – 6.32) *** 3.81 (2.43 – 5.96) *** 2.29 (1.59 – 3.27) *** 2.22 (1.55 – 3.18) ***

* p < 0.10; ** p < 0.05; *** p < 0.001
a

95% Confidence Interval
In a model adjusting for other predictors RRA for NAA–Asthma interaction among WNH women 1.11 (0.57 – 2.16)
In a model adjusting for other predictors RRA for NAA–Asthma interaction among BNH women 0.85 (0.49 – 1.47)
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Table 24: Maternal Demographic and Clinical Characteristics by Control Category
Characteristic
SC
RC
(N = 7,972)
(N = 55,685)
Sex
Female
Male

48.4%
51.6%

49.1%
50.9%

Mother’s race***
White non – Hispanic
Black non – Hispanic
Hispanic
Other

45.8%
45.2%
7.9%
1.1%

46.2%
43.5%
9.1%
1.2%

Smoking prior to pregnancy

18.8%

18.8%

Smoking during pregnancy

14.6%

14.4%

Pre–pregnancy diabetes

0.7%

0.7%

Gestational diabetes

3.3%

3.3%

Pre–pregnancy hypertension**

2.0%

1.7%

15.5%

2.7%

Asthma***
*p < 0.10; **p < 0.05; ***p < 0.001

Table 25: Study Outcomes by Control Category
Characteristic

SC
(N = 7,972)

RC
(N = 55,685)

4.4%

4.3%

2.0%

2.0%

9.5%

9.2%

a

Low birth weight
SGA

b

Preterm birth
a

For infants born after completing 37 weeks of gestation; N = 7,210 and 50,559 for SC and RC
respectively
b
Birth weight less than 2 standard deviations from the sex– and gestational age–specific mean
*p < 0.10; **p < 0.05; ***p < 0.001
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Figure 1: Percent of Mothers with a Non – Asthmatic Atopy by Infant Birth Weight
p < 0.001 for increasing trend
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Figure 2: Percent of Mothers with Asthma by Infant Birth Weight
p < 0.001 for decreasing trend
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Figure 3: Percent of Mothers with a Non – Asthmatic Atopy by Infant Gestational Age at Birth
p < 0.001 for increasing trend
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Figure 4: Percent of Mothers with a Non – Asthmatic Atopy by Fetuses at Risk for Gestational Age
at Birth
p < 0.001 for overall increasing trend
p < 0.001 for increasing trend for gestational age at birth < 36 weeks
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Figure 5: Percent of Mothers with Asthma by Infant Gestational Age at Birth of Offspring
p < 0.001 for decreasing trend
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Figure 6: Percent of Mothers with Asthma by Fetuses at Risk for Gestational Age at Birth
p < 0.001 for overall increasing trend
p < 0.001 for increasing trend for gestational age at birth < 36 weeks
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Figure 7: Percent of Mothers with Non – Asthmatic Atopy by Infant Birth Weight by
Race/Ethnicity
p < 0.001 for increasing trend among WNH mothers
p < 0.001 for increasing trend among BNH mothers
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Figure 8: Percent of Mothers with Asthma by Infant Birth Weight by Race/Ethnicity
p < 0.001 for decreasing trend among WNH mothers
p < 0.001 for decreasing trend among BNH mothers
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Figure 9: Percent of Mothers with Non – Asthmatic Atopy by Infant Gestational Age at Birth by
Race/Ethnicity
p < 0.001 for increasing trend among WNH mothers
p < 0.001 for increasing trend among BNH mothers
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Figure 10: Percent of Mothers with a Non – Asthmatic Atopy by Fetuses at Risk for Gestational
Age at Birth by Race/Ethnicity
p < 0.001 for overall increasing trend among WNH mothers
p < 0.001 for overall increasing trend among BNH mothers
p < 0.001 for increasing trend for gestational age at birth < 36 weeks among WNH mothers
p < 0.001 for increasing trend for gestational age at birth < 36 weeks among BNH mothers
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Figure 11: Percent of Mothers with Asthma by Infant Gestational Age at Birth by Race/Ethnicity
p < 0.001 for decreasing trend among WNH mothers
p < 0.001 for decreasing trend among BNH mothers
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Figure 12: Percent of Mothers with Asthma by Fetuses at Risk for Gestational Age at Birth by
Race/Ethnicity
p < 0.001 for overall increasing trend among WNH mothers
p < 0.001 for overall increasing trend among BNH mothers
p < 0.001 for increasing trend for gestational age at birth < 36 weeks among WNH mothers
p < 0.001 for increasing trend for gestational age at birth < 36 weeks among BNH mothers
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CHAPTER FIVE: DISCUSSION

5.1

FINDINGS CONSISTENT WITH THE LITERATURE

5.1.1

MAJOR FINDINGS CONSISTENT WITH THE LITERATURE
The statistical models used in this study quantified a protective but not statistically

significant, effect of non – asthmatic atopy (NAA) on all study outcomes. When considering the
conditions separately, both allergic rhinitis (AR) and atopic dermatitis (AD) were estimated to have
mildly protective effects (RRA = 0.91 and 0.98 resp.) on PTB. These estimates were not statistically
significant. In their study Trønnes et al found AR and AD to be protective against PTB (RR = 0.84
and 0.90 respectively) (Trønnes et al., 2014). This study found a higher prevalence of AR among
WNH mothers compared to BNH mothers (12.4% vs. 10.7%, p < 0.05) and a higher prevalence of
AD among BNH mothers compared to WNH mothers (11.1% vs. 8.8%, p < 0.001). This is
consistent with previous research. Hjern et al found that AR was more prevalent among persons of
European and Australian descent (Hjern et al., 2000). While Williams et al found that AD is more
prevalent among persons of African descent (Williams et al., 1999).
This study found similar trends as did Savilahti et al. In their 2004 study, Savilhati et al
found that mothers of very low birth weight infants had significantly less atopy than mothers of full
term infants (AR; 27% vs. 34% resp., AD; 29% vs. 33% resp.) (Savilahti et al., 2004). This study also
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found that the mothers of very low birth weight infants had less atopy than the mothers of full term
infants (AR; 8.72% vs. 11.00% resp., AD; 6.76% vs. 9.64% resp.), however these results were not
statistically significant. This study did however find a statistically significant increasing trend of the
percentage of mothers with non – asthmatic atopy across infant birth weight. Mothers with heavier
babies at birth had higher percentages of NAA. This study also found a similar trend across infant
gestational ages at birth. Mothers who gave birth later had higher percentages with non – asthmatic
atopy. And further the percentages of mothers with NAA dropped sharply after 40 weeks of
gestation.
The statistical models used in this study estimated that asthma increased the risk each study
outcome; LBW (RRA = 1.05; p > 0.05), SGA (RRA = 1.11; p > 0.05), and PTB (RRA = 1.20; p = 0.03).
This increased risk of asthma on PTB was comparable to the effect found by both Murphy et al in
their 2011 study (RR = 1.41) (V. Murphy et al., 2011) and Trønnes et al in their 2014 study (RR =
1.15) (Trønnes et al., 2014). The increased risk that asthma has SGA, was also comparable to the
effect found by Murphy (RR = 1.22) (V. Murphy et al., 2011). A statistically significant decreasing
trend of the percentages of mothers with asthma across infant birth weight was also detected. There
was a similar decreasing trend across infant gestational ages at birth. Mothers who gave birth earlier
had higher percentages with asthma. See Appendix A for a summary findings consistent with the
literature.

5.1.2

OTHER FINDINGS CONSISTENT WITH THE LITERATURE
The proportion of infants in this study that were born with low birth weight was 10.1%.

This proportion is comparable to the 2014 State average of 9.7% (CDC, 2015a), but different from
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the 2014 national rate of 8.0% (CDC, 2015a). Among infants who were born after completing at
least 37 weeks of gestation, the proportion born with low birth weight was 4.4%.
This study found that approximately 20% of participants smoked before pregnancy and that
approximately 15% continued to smoke during pregnancy. These estimates are consistent with
percentages of between 12% to 22% of women and girls smoking that is found in the literature
(CDC, 2004) and further that between 18% and 25% quit once they become pregnant (CDC, 2004).
It is well documented that smoking during pregnancy increases the risk of adverse pregnancy
outcomes including LBW, SGA and PTB (SILVERMAN, 1977). This study found that smoking
during pregnancy increased the risks of LBW and SGA. These estimated increases in risk remained
statistically significant among WNH women only when the data was analyzed by maternal
race/ethnicity. This could be due to the higher prevalence of smoking during pregnancy found
among WNH women compared to BNH women (25% vs. 6%).
Chronic diseases such as diabetes and pre – pregnancy hypertension were found to increase
the risks of SGA and PTB, while pre – pregnancy hypertension was found to also increase the risk
of LBW. These findings are consistent with the literature indicating that these types of chronic
diseases in the mother put them at increased risk for adverse pregnancy outcomes (Casson et al.,
1997; Yogev & Visser, 2009). In addition to this, this study found that pre – pregnancy hypertension
was associated with a statistically significant increase in the risks of SGA and PTB among both WNH
and BNH women. While gestational diabetes was found to increase the risk of PTB and this
increased risk remained statistically significant among BNH women only when the data was analyzed
by maternal race/ethnicity. See Appendix A for a summary of findings consistent with the literature.
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5.2

FINDINGS WHICH DIFFER FROM THE LITERATURE

5.2.1

MAJOR FINDINGS WHICH DIFFER FROM THE LITERATURE
The estimated prevalence of atopy (allergic rhinitis, atopic dermatitis and asthma) found

among this population is 7.20% which is approximately one–third the estimates given in the
literature of between 20 and 25% of the general adult population aged 16 to 65 years (Franzese,
2011). This estimate is in keeping with the fact that this study was restricted to women between the
ages of 19 & 25. In addition to this allergic rhinitis is often both underdiagnosed and misdiagnosed
(Greiner et al., 2012). The prevalence of non – asthmatic atopy in this population is estimated to be
3.0%. This estimate is much lower than the estimated found in the literature (Franzese, 2011; Ruby
Pawankar et al., 2012).
The estimated prevalence of asthma found in this study was 4.6%. This is very different from
the 7.0% of adults estimated by the CDC (CDC, 2013a) and the prevalence of between 8% and
13% worldwide found by Murphy et al (V. E. Murphy & Gibson, 2011). This could also be due to
the fact that only a portion of all adults would be represented in the study cohort; i.e. mothers
between the ages of 19 and 25 years, and, further, asthma prevalence rates for this specific age group
are not available.
This study found that approximately 15.5% of persons with NAA also have asthma. This is
lower than the estimated 40% in the literature (Kim et al., 2008; Ruby Pawankar, 2002). This
suggests that at least 60% of women who do not have asthma with NAA may have the benefit of
reduced risk of adverse pregnancy outcomes.
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Also found was the fact that 10.1% of women who had asthma also had another atopy. This
is markedly less than estimates ranging between 30% and 80% (Kim et al., 2008) in the literature.
Health professionals should, therefore, seek to identify other forms of atopy that may be diagnosable
at the same time as asthma, since the findings of this study suggest that the presence of NAA along
with asthma may reduce the negative effect that asthma has on pregnancy outcomes for some women
and exacerbate this effect for others.
Very interestingly, this study study found that asthma increased the risk of LBW among
WNH women and not BNH women (RRA = 1.29 and 0.96 resp.), while Aly et al found the reverse
trend that asthma increased the odds of LBW among BNH women and not WNH women (OR =
1.7 and 0.99 resp.). See Appendix B for a summary of findings which differ from the literature.

5.2.2

OTHER FINDINGS WHICH DIFFER FROM THE LITERATURE
The proportion of infants in this study that were born preterm was 9.5% which is different

and less than the estimated State prevalence of 13.75% (CDC, 2015a) and the estimated national
prevalence of 11.4% (CDC, 2015a). This discrepancy in the prevalence of preterm birth can be
explained by the fact that mothers studied were between the ages of 19 and 25 years and the
prevalence of preterm birth tends to be higher among older women (CDC, 2014b). This discrepancy
could also be due to the fact that the births examined in this study occurred over a 10 – year period
and further only included a subset of all births i.e. mother’s first live birth. See Appendix B for a
summary of findings which differ from the literature.
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5.3

STUDY STRENGTHS
This study had the strength of drawing information from two large databases producing

more than 60,000 records. The Medicaid database has the primary purpose of being used
administratively and not for research and as such is less likely to contain systematic biases in
diagnosis codes. The quality of the data was good within variables used to calculate study outcomes,
LBW, SGA and PTB being complete i.e. less than 1% of data missing. Further, complete
information was available for 97.5% of all maternal records found. Data on other characteristics
such as maternal age, race/ethnicity, smoking, diabetes and hypertension was also complete with
less than 1% of data missing.
The major findings of this study suggest that the data are internally valid. This is evidenced
by the fact that the investigated condition; NAA affects all outcomes in a similar way. This study also
found that AR is more prevalent among WNH and AD is more prevalent among BNH, both these
findings are consistent with the literature. It can also be inferred that the data accuracy was good as
findings about other factors that have been previously documented such as, smoking, hypertension
and diabetes are consistent with current literature (see Appendix A). The findings in this study are
consistent with the literature that maternal smoking increases the risk of infants being born LBW
and SGA. This is a phenomenon which has persisted in the literature since 1977. It has also been
relatively well documented over the past 20 years that chronic conditions in the mother such as
diabetes and hypertension are associated with increased risk of adverse pregnancy outcomes such as
LBW, SGA and PTB. The findings of this study are consistent with that. The data used in this study
also produced statistics consistent with estimates from 2004 on the percent of women who smoke
as well as the percent who smoke during pregnancy (see Appendix A). These data also displayed
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similar trends as previously published data from 2004 on how atopy was likely to be associated with
birth weight and fetal development. Analyses also confirmed what previous research had found with
respect to asthma being associated with an increased risk of PTB. The estimated State prevalence of
LBW was also consistent with the most recent CDC estimate of same (see Appendix A). These
findings that are both in agreement with data from varying time periods i.e. 1970s, 1990s, 2000s,
and the fact that risk estimates are consistent with previously published findings, provide evidence
that the data used are accurate and contain no systematic bias that would otherwise explain the
results. This further suggests that information on NAA is also credible.
Study investigators are also confident that no systematic bias was introduced during data
selection and data cleaning. The distributions of study outcomes and other characteristics, with the
exception of pre – pregnancy hypertension, remained consistent when examining the controls who
were selected for the primary analysis (selected controls, SC) and comparing them to the controls
who were not selected for the primary analysis (remaining controls, RC). There was a slightly higher
rate of pre – pregnancy hypertension in SC when compared to RC (2.0% vs. 1.7%, p < 0.05). The
magnitude of this difference is very slight and the distribution of pre – pregnancy hypertension was
not statistically different between the NAA group and the SC group. In addition to this, pre –
pregnancy hypertension was one of the conditions controlled for in the statistical models that were
used to estimate the risk of each outcome. Again this provides evidence that the differences
estimated were in fact due to NAA status.
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5.4

FINDINGS RELATED TO LIMITATIONS
There were findings that could not be verified as data on the specific age group examined in

this study are not available. The proportion of women with diabetes in this study was estimated to
be 0.7%. This is an acceptable estimate of the proportion of women with diabetes who are between
the 19 and 25 years, as the prevalence of diabetes among women under the age of 44 years was
estimated to be 1.5% in 2014 (CDC, 2015b). This study estimated that the proportion of women
with gestational diabetes was approximately 3.3%. This is also a plausible estimate as the prevalence
of gestational diabetes among all pregnant women was estimated to be 9.2% in 2010 (DeSisto, 2014).
Within this study population, the proportion of women with hypertension was 2.0%. Again, while
not verifiable this estimate is reasonable given that it was estimated that 6.8% of women between
the ages of 20 and 34 years have hypertension (CDC, 2015c). See Appendix C for findings related
to limitations.
In addition to information that was known but could not be verified due to unavailable age
– specific data, there was information that was not known, and, therefore, could not be controlled
for. There was no information on the severity of each atopic disease. Likewise, there was no specific
information on timing of symptom onset. I.e. did mothers experience symptoms in particular
trimesters of pregnancy or throughout their entire pregnancies? The only available information on
diagnosis is that it was at least 1 year prior to pregnancy. This study was not able to assess and control
for medication taken by the mother to treat NAA or study outcomes. In addition, this study could
not control for geographical effects including: place of residence, duration at residence, place of
birth; which may affect the severity of atopic conditions.
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5.5

IMPLICATIONS FOR PUBLIC HEALTH
The results of this study indicate that there is a need for increased monitoring and

surveillance of atopic conditions, not just asthma, but also allergic rhinitis and atopic dermatitis.
Many of the findings are new, and, there is no information that has been published about these
effects. This study found that NAA reduces the risk of LBW and SGA among WNH women (RRA
= 0.95 and 0.97 resp.). NAA was also found to reduce the risk of LBW and SGA among BNH
women (RRA = 0.94 and 0.84 resp.). NAA was not found to affect the risk of PTB among BNH
women (RRA = 1.0).
The findings of this study also suggest that the interaction between atopic conditions may
differ according to race/ethnicity. This study found that the interaction between asthma and other
atopic conditions increased the risk of LBW, SGA and PTB among WNH women (RRA = 1.40, 1.87
and 1.11 resp.). However, this same interaction was found to reduce the risk of LBW, SGA and PTB
among BNH (RRA = 0.79, 0.19 and 0.85 resp.). This apparent discrepancy in effect could be due to
treatment which, as previously mentioned this study was unable to assess. The prevalence of each
study outcome was higher among BNH mothers when compared to WNH mothers. It is, therefore,
possible that a BNH mother diagnosed with more than one atopy, was treated with medication or,
some other intervention for at least one atopy, or another type of intervention that would affect the
study outcomes, was implemented. Murphy et al found that asthma medication was effective in
reducing the risk of LBW (V. Murphy et al., 2011) and Bakhireva et al found that PTB was associated
with poor asthma symptom control and not just a diagnosis of asthma (Bakhireva et al., 2008). This
suggests that the way in which asthma along with NAA modified the risk of each study outcome,
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was different for WNH women when compared to BNH women who had asthma along with another
atopy. It is plausible that the interactions of different types of atopy would affect WNH women and
BNH women differently due to biological differences across race/ethnicity. This has been found to
be the case with smoking cigarettes and the subsequent metabolism of cotinine. Researchers have
found that there are higher levels of cotinine detected in the blood of blacks for each cigarette
smoked when compared to whites (Perez-Stable, Herrera, Jacob III, & Benowitz, 1998).
It is also possible that atopic conditions may interact with other health conditions. This study
suggests that there is an underlying mechanism between atopy and pregnancy outcome, which may
vary by race/ethnicity and access to health care. This study estimated a low prevalence of NAA
although previous research suggests that the prevalence of NAAA is much higher and increasing
among the general population, and, hence, women. This low prevalence can be explained by the fact
that atopy, particularly AR and AD are not screened for, and, hence, not actively managed unless
the patient is manifesting symptoms. If the presence of NAA could provide protection against the
adverse pregnancy outcomes studied here, then a diagnosis of NAA should be taken into account
when assessing a woman’s risk of an adverse outcome.
It is well established that uncontrolled asthma increases the risk of adverse pregnancy
outcomes. The protective effect of other atopic conditions may be overlooked because asthma is also
present, and more actively managed. While it is possible to have single atopic conditions, it has been
hypothesized that they are interrelated in such a way, that careful management of one condition is
beneficial in reducing the symptoms of another (i.e. management of AR is essential to effective
asthma control and vice versa). Further, current trends suggest that these conditions can develop or
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manifest at any age, and therefore should not be overlooked in achieving optimal health care for
patients.

5.5.1

FUTURE DIRECTIONS
It can be deduced that the maternal immune system is heavily involved in the successful

completion of a pregnancy (Savilahti et al., 2004), and there may be several reasons for the apparent
protective effect of NAA on pregnancy. Firstly, the proportion of mothers diagnosed with NAA is
relatively low, supporting previous research that NAA, in particular AR is often underdiagnosed
(Greiner et al., 2012). It is possible that mothers actually receiving such as diagnosis are the ones
who are more severely affected, and, therefore, more actively seek out medical care. This leads to an
increase in both preconception and prenatal care which have been shown to improve health
outcomes for both the mother and child (Bhutta, Dean, Imam, & Lassi, 2011; Salihu, Myers, &
August, 2012). However, the controls in this study would also have received a similar amount of
preconception and prenatal care and so this still suggests that the benefits observed are in fact due
to NAA providing protection against adverse pregnancy outcomes.
Another possible explanation for the apparent protective effect is the biological process
associated with these two immune responses. Both AR and AD are associated with a T – helper 2
cell dominant humoral responses from the immune system (Savilahti et al., 2004; Trønnes et al.,
2014). This response is less associated with inflammation and more so with an increase in mucus
production. Mucus production assists in removing pathogens that may prove harmful to the
pregnancy. This shift in immune response is also beneficial for the pregnancy in avoiding fetal
rejection that is more likely in a T – helper 1 cell dominant immune response (Warner, Jones,
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Williams, & Warner, 1998). This has gone unnoticed for the most part mainly due to the fact that
in many instances when persons have NAA they also have asthma, and the benefit of NAA is hidden
behind the adverse effects of asthma.
It is also plausible that persons diagnosed with allergies make lifestyle adjustments in order
to avoid triggers which produce at the very least uncomfortable symptoms. These adjustments lead
to an improved environment which includes the avoidance of pathogens that may be harmful to the
pregnancy. This is, however, not the whole story as there is a lack of knowledge to the role that the
external environment plays in allergic sensitization and the manifestation of associated symptoms.
Persons who are exposed to pathogens early on in life such as having a pet or living on a farm, have
been shown to suffer less from allergic disorders (Gordon, 2011). This protection however has been
shown to not be lifelong, and may decrease as the exposure to the familiar pathogens decreases,
making a person become more sensitive and prone to developing an allergic disorder (Douwes et al.,
2007; Eriksson et al., 2010). It is plausible that the immune system which now being idle, not having
pathogens consistently to contend with; overreacts when it does come into contact with a previously
very familiar pathogen. It stands ready so to speak to attack, leading to increased protection in the
case of an expectant mother albeit accompanied by annoying and possibly uncomfortable symptoms.
In order to further explore the relationship between NAA and pregnancy outcomes and
address some of the limitations of this study, it would be beneficial to enroll a prospective cohort of
women expanding the age range of participants, where dates of diagnosis, severity of symptoms,
Immunoglobulin E levels can be measured and timing of symptoms are known.
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I would also like to explore the postulated allergic continuum. It has been hypothesized that
there is an order to developing allergic responses with AD being the first stage, and asthma being
the final. I would like to further investigate this in the population.
I would also like to explore how taking medication to treat the symptoms of NAA may affect
fetal development and pregnancy outcomes. Research up to this point has not been able to address
what would constitute best practices with regard to treating asthma during pregnancy, and, further,
no studies have been conducted to evaluate how medication taken to treat allergic rhinitis or atopic
dermatitis may affect pregnancy outcomes. In order to address this question it would be helpful to
have access to patients’ pharmacologic data over time. This database would ideally contain both
prescription medicines and those obtained over the counter. This would provide a means to not
only investigate how treatments for NAA may affect the study results, but also, to adequately control
for, and explain, the effects of other medications that a patient may be taking.

5.6

CONCLUSION
The presence of NAA; AR and/or AD provides protection against adverse pregnancy

outcomes such as low birth weight, small for gestational age and preterm birth. Until now their
protective effect has not been recognized due to the fact that in many cases asthma is also often
present. If asthma can be excluded in assessing maternal risk for adverse pregnancy outcomes, then
the remaining atopic mothers have improved pregnancy outcomes. This is likely due to a positive
influence of the T – helper 2 cell immune response to pathogens from the mother’s immune system
and its interaction with the placenta/fetus.
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Even among some women with asthma, the presence of NAA reduces the negative effect of
asthma on pregnancy outcomes.
This study also suggests that the mechanisms associated with an infant being born LBW,
SGA or PTB include a pathway which can be explained by an active maternal immune system. Even
among non – atopic mothers, immune system activity must include 2 stages during pregnancy.
Firstly, the immune system is initially suppressed early on in the pregnancy to facilitate implantation
and prevent rejection of the fetus; and secondly the immune system’s ability to convert from having
T – helper 1 cell dominant responses to having T – helper 2 cell dominant responses to pathogens
during pregnancy.
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APPENDIX A: FINDINGS CONSISTENT WITH THE LITERATURE
Summary of Finding

Chronic diseases and risks of study
Outcomes

Smoking increases the risks of
LBW and SGA
Diabetes, hypertension increase
risks for LBW, SGA and PTB

Prevalence of AD among different
Ethnicities
Prevalence of AR among different
Ethnicities

AD is more prevalent among BNH
mothers
AR is more prevalent among WNH
mothers

AD is more prevalent among persons
of African descent
AR is more prevalent among persons
of European and Australian descent

Smoking and risks of study outcomes

2.
3.

5.

Literature

Smoking increases the risks of
LBW and SGA
Diabetes, hypertension increase
risks of LBW, SGA and PTB

1.

4.

My Study Finding

The proportion of women who
Smoke
6. The proportion of women who
smoke while pregnant
7. Moms of VLBW infants has less atopy
compared to moms of full term
infants (rates not the same but
trends are)
8. Asthma increases risk of SGA and
PTB
9. Asthma increases risk of PTB
10. AR reduces the risk of PTB
11. AD reduces the risk of PTB
12. The prevalence of LBW in SC

References
Silverman 1977
Casson 1997
Williams 1999
Hjern 2000

19.7%

12% - 22%

CDC 2004

14.7%

18% – 25% quit while pregnant

CDC 2004

AR – 8.72% vs 11.00%,
AD – 6.76% vs. 9.64%

AR – 27% vs 34%,
AD – 29% vs. 33%

Savilahti 2004

RR = 1.11 &1.20 resp.

RR = 1.22 & 1.41 resp.

Murphy 2011

RR = 1.20
RR = 0.91
RR = 0.98
10.1%

RR = 1.15
RR = 0.84
RR = 0.90
9.7%

Trønnes 2014
Trønnes 2014
Trønnes 2014
CDC 2015
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APPENDIX B: FINDINGS WHICH DIFFER FROM THE LITERATURE
Summary of Finding
1. Percentage of persons with NAA who
also have asthma
2. Percentage of persons with asthma who
also have NAA
3. Asthma increases the risk of LBW in
WNH women not BNH women
4. The prevalence of atopy
5. The prevalence of NAA
6. The prevalence of asthma
7. The prevalence of PTB in SC

My Study Finding

Literature

References

15.5%

40%

Pawankar 2002

10.1%

30% – 80%

Kim 2008

RR = 1.29 (WNH)
RR = 0.96 (BNH)
7.20%
3.0%
4.6%
9.5%

OR = 0.99 (WNH)
OR = 1.70 (BNH)
20% – 25%
20% – 30%
8% – 13%
13.75%
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Aly 2011
Franzese 2011
Greiner 2012
Murphy 2011
CDC 2015

APPENDIX C: FINDINGS RELATED TO LIMITATIONS (THIS STUDY WAS AGE RESTRICTED)
Summary of finding
1. The proportion of women
with gestational diabetes
2. The proportion of women
with diabetes
3. The proportion of women
with hypertension

My Study Finding
3.3%
0.7%
2.0%

Literature
9.2% among all pregnant
women
1.5% among women
under 44 years
6.8% among women
aged 20 – 34 years
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References
DeSisto 2010
CDC 2015
CDC 2015

APPENDIX D: FINDINGS RELATED TO FUTURE DIRECTIONS (NO PREVIOUS
DATA)
Summary of Finding

My Study Finding

1. NAA reduces the risk of LBW & SGA among
WNH women
2. NAA reduces the risk of LBW & SGA among
BNH women
3. NAA does not affect the risk of PTB among
BNH women
4. NAA with asthma is protective against LBW,
SGA & PTB for BNH women
5. NAA with asthma increases the risk of LBW,
SGA & PTB for WNH women
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RR = 0.95 & 0.97 resp.
RR = 0.94 & 0.84 resp.
RR = 1.0
RR = 0.79, 0.19, 0.85 resp.
RR = 1.40, 1.87, 1.11 resp.

APPENDIX E: DATA SELECTION

MEDICAID DATABASE

VITAL STATS DATABASE

MATERNAL INFORMATION

INFANT OUTCOMES
PRIMIPAROUS BIRTHS OCCURRING
JAN 1, 2004 - JAN 1, 2014

(N = 67,281)

(N = 67,771)

Plural birth
(n = 1,369)

Plurality missing
(n = 543)
SINGLETON BIRTHS
(N = 65,859)

Gestational age < 24 weeks
(n = 165)
Gestational age missing
(n = 36)
Birth weight missing
(n = 8)
COMPLETE
MATERNAL - INFANT DYADS
(N = 65,650)

Figure 13: Data Selection Step 1
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COMPLETE
MATERNAL - INFANT DYADS
(N = 65,650)

NAA+ MOTHERS

NAA- MOTHERS

(N = 1,993)

(N = 63,657)

SELECTED CONTROLS (SC)

REMAINING CONTROLS (RC)

Frequency matched 1:4 to
NAA+ on age, sex of infant &
asthma
(N = 7,972)

PRIMARY DATASET
USED IN ANALYSIS
(N = 9,965)

Figure 14: Data Selection Step 2
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(N = 55,685)

APPENDIX F: ADDITIONAL STUDY TABLES

Table 26: ICD Codes Used to Classify Patients as having a Non–Asthmatic Atopy
ICD 9 Code Explanation
AR/AD
370.31
372.03
372.05
372.13
372.14
373.31
373.32
477.0
477.1
477.2
477.8
477.9
691
691.8
692.84
692.9
693.1

Phylctenular Keratoconjunctivitis
Mucopurulent Conjunctivitis – other
Acute Atopic Conjunctivitis
Vernal Conjunctivitis
Chronic Allergic Conjunctivitis
Eczematous Dermatitis – eyelid
Contact and Allergic Dermatitis of the eyelid
Allergic Rhinitis – pollen
Allergic Rhinitis – food
Allergic Rhinitis – animal hair/dander
Allergic Rhinitis – other allergen
Allergic Rhinitis – cause unspecified
Atopic Dermatitis
Atopic Dermatitis
Contact Dermatitis – animal hair/dander
Contact Dermatitis – unspecified
Dermatitis – food
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AD
AD
AD
AD
AD
AD
AD
AR
AR
AR
AR
AR
AD
AD
AD
AD
AD

Table 27: Summary of Numeric Characteristics
Characteristic
Summary
N

9965

Mother’s age (years)
Range
Mean + SD

19 – 25
20.8 + 1.8

Gestational age at birth (weeks)
Range
Mean + SD

24 – 43
38.6 + 2.0

Birth weight (grams)
Range
Mean + SD
Number of non – asthmatic disorders
Range
Median + IQR

140 – 6719
3155.1 + 568.4
0–4
0+0
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Table 28: Maternal Demographic and Clinical Characteristics (N = 9965)
Characteristic
n (%)
Mother’s age (years)
19
20
21
22
23
24
25

3,005 (30.2)
2,260 (22.7)
1,505 (15.1)
1,300 (13.1)
790 (7.9)
585 (5.9)
520 (5.2)

Sex of infant
Female
Male

4,825 (48.4)
5,140 (51.6)

Mother’s race
White non – Hispanic
Black non – Hispanic
Hispanic
Other

4,607 (46.3)
4,556 (45.7)
698 (7.0)
100 (1.0)

Smoking prior to pregnancy

1,938 (19.5)

Smoking during pregnancy

1,468 (14.7)

Pre–pregnancy diabetes

70 ( 0.7)

Gestational diabetes

329 (3.3)

Pre–pregnancy hypertension

201 (2.0)

Asthma

1,545 (15.5)

100

Table 29: Characteristics by Atopy Category
Characteristic
Non – Asthmatic Atopy
Present/Cases Absent/Controls
(N = 1,993)
(N = 7,972)
Mother’s age (years)
Range
Mean + SD
Gestational age at birth
(weeks)
Range
Mean + SD
Birth weight (grams)
Range
Mean + SD

19 – 25
20.8 + 1.8

19 – 25
20.8 + 1.8

Asthma
Present
(N = 1,545)

Absent
(N = 8,420)

19 – 25
20.9 + 1.8

19 – 25
20.8 + 1.8
***

24 – 42
38.6 + 2.0

24 – 43
38.6 +2.0

24 – 41
38.4 + 2.1

24 – 43
38.6 + 2.0
***

420 – 5018
3170.7 + 560.8

140 – 6719
3151.2 + 570.3

*p < 0.10; **p < 0.05; ***p < 0.001

101

775 – 6,332
3,091.6 +
580.0

140 – 6,719
3,166.7 +
565.5

Table 30: Maternal Demographic and Clinical Characteristics by Atopy Category
Characteristic
Non–Asthmatic Atopy
Present/Cases
Absent/Controls
(N = 1,993)
(N = 7,972)

Asthma
Present
(N = 1,545)

Sex
Female
Male
Mother’s race
White non – Hispanic
Black non – Hispanic
Hispanic
Other
Smoked prior to pregnancy
Yes
Smoked during pregnancy
Yes
Pre–pregnancy diabetes present
Yes
Gestational diabetes present
Yes
Pre–pregnancy hypertension present
Yes
Asthma present
Yes
*p < 0.10; **p < 0.05; ***p < 0.001

Absent
(N = 8,420)
***

48.4%
51.6%

48.4%
51.6%

52.4%
47.6%

***

47.7%
52.3%
***

48.2%
48.0%
3.3%
0.6%

45.8%
45.2%
7.9%
1.1%

44.3%
51.5%
3.6%
0.7%

**

46.6%
44.7%
7.6%
1.1%
***

21.4%

19.0%

23.4%

18.8%
***

15.2%

14.6%

18.8%

14.0%
**

0.8%

0.7%

1.3%

0.6%

3.4%

3.3%

3.2%

3.3%

2.1%

2.0%

3.1%

1.8%

15.5%

15.5%

–

–

**

102

Table 31: Characteristics by NAA type
Characteristic

a

a

Allergic Rhinitis
Present
Absent
(N = 1,093)
(N = 8,872)

Atopic Dermatitis
Present
Absent
(N = 959)
(N = 9,006)

Mother’s age (years)
Mean + SD

20.9 + 1.8

20.8 + 1.8

20.8 + 1.7

20.8 + 1.8

Gestational age at birth (weeks)
Mean + SD

38.5 + 2.0

38.6 +2.0

38.6 + 1.9

38.6 + 2.0

3176.2 + 563.3

3152.5 + 569.0

3161.3 + 561.6

3154.4 + 569.1

Birth weight (grams)
Mean + SD
a

Each condition was considered separately
*p < 0.10; **p < 0.05; ***p < 0.001

Table 32: Study Outcomes by Atopy Types and Combinations
Outcome

PTB

AR Present
Asthma
No Asthma

AR Absent
Asthma
No Asthma

(N = 1,545)

(N = 8,420)

(N = 232)

(N = 861)

(N = 1,313)

(N = 7,559)

a

4.9%

4.3%

3.9%

4.6%

5.1%

4.2%

b

2.4%

2.0%

1.7%

2.4%

2.5%

1.9%

11.5%

9.1% **

12.5%

8.5% *

11.4%

9.2% **

LBW
SGA

Asthma
Present
Absent

a

For infants born after completing 37 weeks of gestation; N = 1,367 and 7,650 for Asthma present
and absent respectively; N = 203 and 788 for Asthma present and absent respectively among
mothers with AR; N = 1,164 and 6,862 for Asthma present and absent respectively among
mothers without AR.
b
Birth weight less than 2 standard deviations from the sex– and gestational age–specific mean
*p < 0.10; **p < 0.05; ***p < 0.001
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Table 33: Study Outcomes by Atopy Types and Combinations
Outcome

PTB

AD Present
Asthma
No Asthma

AD Absent
Asthma
No Asthma

(N = 1,545)

(N = 8,420)

(N = 100)

(N = 859)

(N = 1,445)

(N = 7,561)

a

4.9%

4.3%

8.9%

4.0% *

4.6%

4.3%

b

2.4%

2.0%

3.0%

1.8%

2.4%

2.0%

11.5%

9.1% **

10.1%

9.3%

11.6%

9.1% **

LBW
SGA

Asthma
Present
Absent

a

For infants born after completing 37 weeks of gestation; N = 1,367 and 7,650 for Asthma present
and absent respectively; N = 90 and 779 for Asthma present and absent respectively among
mothers with AD; N = 1,277 and 6,871 for Asthma present and absent respectively among
mothers without AD.
b
Birth weight less than 2 standard deviations from the sex– and gestational age–specific mean
*p < 0.10; **p < 0.05; ***p < 0.001

Table 34: Summary of Numeric Characteristics by Maternal Race/Ethnicity
Characteristic
WNH
BNH
N

4,607

4,556

Mother’s age (years) **
Range
Mean + SD

19 – 25
20.9 + 1.8

19 – 25
20.8 + 1.7

Gestational age at birth (weeks) ***
Range
Mean + SD

24 – 43
38.7 + 1.9

24 – 42
38.4 + 2.2

506 – 5,018
3,260.3 + 551.1

140 – 6,719
3,033.7 + 575.5

0–3
0+0

0–4
0+0

Birth weight (grams) ***
Range
Mean + SD
No. of non – asthmatic disorders
Range
Median + IQR
*p < 0.10; **p < 0.05; ***p < 0.001
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Table 35: Maternal Demographic and Clinical Characteristics by Maternal Race/Ethnicity
Characteristic
WNH
BNH
(N = 4,607)
(N = 4,556)
n (%)
n (%)
Sex
Female
Male

2,211 (48.0)
2,396 (52.0)

2,228 (48.9)
2,328 (51.1)

Smoking prior to pregnancy ***

1,478 (32.1)

398 (8.7)

Smoking during pregnancy ***

1,152 (25.0)

274 (6.0)

Pre–pregnancy diabetes **

25 ( 0.5)

43 ( 0.9)

Gestational diabetes *

137 (3.0)

166 (3.6)

Pre–pregnancy hypertension ***

64 (1.4)

128 (2.8)

Asthma **
*p < 0.10; **p < 0.05; ***p < 0.001

684 (14.9)

796 (17.5)
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Table 36: Summary of Characteristics by Atopy Category by Maternal Race/Ethnicity
Characteristic
WNH
BNH
NAA Present NAA Absent NAA Present NAA Absent
(N = 960)
(N = 3,647)
(N = 957)
(N = 3,599)
Mother’s age (years)
Range
Mean + SD

19 – 25
20.9 + 1.8

19 – 25
20.9 + 1.8

19 – 25
20.8 + 1.8

19 – 25
20.8 + 1.7

Gestational age at birth (weeks)
Range
Mean + SD

24 – 42
38.7 + 1.8

24 – 43
38.7 +1.9

24 – 42
38.4 + 2.1

24 – 42
38.4 +2.2

725 – 5,018

506 – 4,819

420 – 4,700

140 – 6,719

3,288.2 + 537.1

3,252.9 + 554.5

3,053.5 + 563.1

3,028.5 + 578.7

Birth weight (grams)
Range
Mean + SD

*

*p < 0.10; **p < 0.05; ***p < 0.001
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Table 37: Maternal Demographic and Clinical Characteristics by NAA Category by Maternal
Race/Ethnicity
Characteristic
WNH
BNH
NAA Present
NAA Absent NAA Present NAA Absent
(N = 960)
(N = 3,647)
(N = 957)
(N = 3,594)
Sex
Female
Male

48.3%
51.7%

47.9%
52.1%

48.3%
51.7%

49.1%
50.9%

Smoking prior to pregnancy

33.2%

31.8%

9.6%

8.5%

Smoking during pregnancy

24.3%

25.2%

6.3%

6.0%

Pre–pregnancy diabetes

0.8%

0.5%

0.7%

1.0%

Gestational diabetes

3.0%

3.0%

3.8%

3.6%

Pre–pregnancy hypertension

2.0%

1.2% *

2.3%

3.0%

13.2%

15.3%

17.4%

17.5%

Asthma
*p < 0.10; **p < 0.05; ***p < 0.001
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Table 38: Study Outcomes by Atopy Types and Combinations among WNH women
Outcome

Asthma
Present
Absent

AR Present
Asthma
No Asthma

AR Absent
Asthma
No Asthma

(N = 684)

(N = 3,923)

(N = 101)

(N = 471)

(N = 583)

(N = 3,452)

a

3.9%

2.8%

4.4%

2.5%

3.8%

2.8%

b

2.3%

1.5% *

3.0%

1.3%

2.2%

1.5%

10.1%

8.1% *

9.9%

7.6%

10.1%

8.2%

LBW
SGA
PTB
a

For infants born after completing 37 weeks of gestation; N = 615 and 3,605 for Asthma present
and absent respectively; N = 91 and 435 for Asthma present and absent respectively among
mothers with AR; N = 524 and 3,170 for Asthma present and absent respectively among mothers
without AR.
b
Birth weight less than 2 standard deviations from the sex– and gestational age–specific mean
*p < 0.10; **p < 0.05; ***p < 0.001

Table 39: Study Outcomes by Atopy Types and Combinations among BNH women
Outcome
Asthma
AR Present
AR Absent
Present
Absent
Asthma
No Asthma
Asthma
No Asthma
(N = 796)

(N = 3,759)

(N = 120)

(N = 369)

(N = 676)

(N = 3,390)

LBWa

5.9%

6.0%

2.9%

6.9%

6.4%

5.9%

b

2.5%

2.5%

0.8%

3.5%

2.8%

2.4%

13.0%

11.0%

15.0%

10.1%

12.6%

11.1%

SGA
PTB
a

For infants born after completing 37 weeks of gestation; N = 693 and 3,348 for Asthma present
and absent respectively; N = 102 and 332 for Asthma present and absent respectively among
mothers with AR; N = 591 and 3,016 for Asthma present and absent respectively among mothers
without AR.
b
Birth weight less than 2 standard deviations from the sex– and gestational age–specific mean
*p < 0.10; **p < 0.05; ***p < 0.001
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Table 40: Study Outcomes by Atopy Types and Combinations among WNH women
Outcome
Asthma
AD Present
AD Absent
Present
Absent
Asthma
No Asthma
Asthma
No Asthma
(N = 684)

(N = 3,923)

(N = 33)

(N = 374)

(N = 651)

(N = 3,549)

a

3.9%

2.8%

10.0%

2.6% *

3.6%

2.8%

b

2.3%

1.5% *

9.1%

1.3% **

2.0%

1.5%

10.1%

8.1% *

9.1%

7.0%

10.1%

8.2% *

LBW
SGA
PTB
a

For infants born after completing 37 weeks of gestation; N = 615 and 3,605 for Asthma present
and absent respectively; N = 30 and 348 for Asthma present and absent respectively among
mothers with AD; N = 585 and 3,257 for Asthma present and absent respectively among mothers
without AD.
b
Birth weight less than 2 standard deviations from the sex– and gestational age–specific mean
*p < 0.10; **p < 0.05; ***p < 0.001

Table 41: Study Outcomes by Atopy Types and Combinations among BNH women
Outcome
Asthma
AD Present
AD Absent
Present
Absent
Asthma
No Asthma
Asthma
No Asthma
(N = 796)

(N = 3,759)

(N = 61)

(N = 446)

(N = 735)

(N = 3,313)

LBWa

5.9%

6.0%

9.1%

5.3%

5.6%

6.1%

b

2.5%

2.5%

0.0%

2.0%

2.7%

2.6%

13.0%

11.0%

10.0%

11.7%

13.2%

10.9% *

SGA
PTB
a

For infants born after completing 37 weeks of gestation; N = 693 and 3,348 for Asthma present
and absent respectively; N = 55 and 394 for Asthma present and absent respectively among
mothers with AD; N = 638 and 2,954 for Asthma present and absent respectively among mothers
without AD.
b
Birth weight less than 2 standard deviations from the sex– and gestational age–specific mean
*p < 0.10; **p < 0.05; ***p < 0.001
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Table 42: Summary of Numeric Characteristics for Selected Controls to Remaining Controls
Characteristic
SC
RC
N

7,972

55,678

Mother’s age (years) ***
Range
Mean + SD

19 – 25
20.8 + 1.8

19 – 25
21.2 + 1.8

Gestational age at birth (weeks)
Range
Mean + SD

24 – 43
38.6 + 2.0

24 – 45
38.6 + 2.0

140 – 6,719
3,151.2 + 570.3

324 – 6,269
3,164.5 + 568.4

Birth weight (grams) *
Range
Mean + SD
*p < 0.10; **p < 0.05; ***p < 0.001
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APPENDIX G: ADDITIONAL STUDY FIGURES
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Figure 15: Percent of Mothers with Allergic Rhinitis by Infant Birth Weight
p < 0.001 for increasing trend
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Figure 16: Percent of Mothers with Atopic Dermatitis by Infant Birth Weight
p < 0.001 for increasing trend
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Figure 17: Percent of Mothers with Allergic Rhinitis by Infant Gestational Age at Birth
p < 0.001 for increasing trend
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Figure 18: Percent of Mothers with Allergic Rhinitis by Fetuses at Risk for Gestational Age at
Birth
p < 0.001 for overall increasing trend
p < 0.001 for increasing trend for gestational age at birth < 36 weeks
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Figure 19: Percent of Mothers with Atopic Dermatitis by Infant Gestational Age at Birth
p < 0.001 for increasing trend
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Figure 20: Percent of Mothers with Atopic Dermatitis by Fetuses at Risk for Gestational Age at
Birth
p < 0.001 for overall increasing trend
p < 0.001 for increasing trend for gestational age at birth < 36 weeks
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Figure 21: Percent of Mother with Allergic Rhinitis by Infant Birth Weight by Race/Ethnicity
p < 0.001 for increasing trend among WNH mothers
p < 0.001 for increasing trend among BNH mothers
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Figure 22: Percent of Mothers with Atopic Dermatitis by Infant Birth Weight by Race/Ethnicity
p < 0.001 for increasing trend among WNH mothers
p < 0.001 for increasing trend among BNH mothers
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Figure 23: Percent of Mothers with Allergic Rhinitis by Infant Gestational Age at Birth by
Race/Ethnicity
p < 0.001 for increasing trend among WNH mothers
p < 0.001 for increasing trend among BNH mothers

119

Black Non - Hispanic Mothers

0

10

Percent

20

30

White Non - Hispanic Mothers

25

30

35

40

45

25

30

35

40

45

Gestational Age at Birth/Weeks

Figure 24: Percent of Mothers with Allergic Rhinitis by Fetuses at Risk for Gestational Age at
Birth by Race/Ethnicity
p < 0.001 for overall increasing trend among WNH mothers
p < 0.001 for overall increasing trend among BNH mothers
p < 0.001 for increasing trend for gestational age at birth < 36 weeks among WNH mothers
p < 0.001 for increasing trend for gestational age at birth < 36 weeks among BNH mothers
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Figure 25: Percent of Mothers with Atopic Dermatitis by Infant Gestational Age at Birth by
Race/Ethnicity
p < 0.001 for increasing trend among WNH mothers
p < 0.001 for decreasing trend among BNH mothers
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Figure 26: Percent of Mothers with Atopic Dermatitis by Fetuses at Risk for Gestational Age at
Birth by Race/Ethnicity
p < 0.001 for overall increasing trend among WNH mothers
p < 0.001 for overall increasing trend among BNH mothers
p < 0.001 for increasing trend for gestational age at birth < 36 weeks among WNH mothers
p < 0.001 for increasing trend for gestational age at birth < 36 weeks among BNH mothers
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APPENDIX H: HISTORY OF MEDICAID IN SOUTH CAROLINA

HISTORY OF MEDICAID
In 1965 Medicaid was created by an addition made to The Social Security Act. Under
Title XIX, 42 U.S.C. §§ 1396 et seq, the federal government provides funds to states to enable
them to provide medical assistance to residents who meet certain eligibility requirements. The
program was created in order to assist states in providing health care to residents who lack the
income and resources to access necessary medical care. Medicaid serves as the nation’s primary
source of health insurance coverage for low–income populations.

SOUTH CAROLINA
As a condition for receipt of Federal funds under Title XIX of the Social Security Act, the
42 CFR 430.10 Department of Health and Human Services; a Single State Agency, is responsible
for the state’s plan for the medical assistance program. It also administers the program in
accordance with the provisions of the State Plan, the requirements of title XI and XIX of the Act,
and all applicable Federal regulations and other official issuances of the Department (July 1, 1995).
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APPENDIX I: LIST OF ABBREVIATIONS AND TERMS USED IN THIS DISSERTATION

ABBREVIATIONS
NAA – Non – Asthmatic Atopy
AR – Allergic Rhinitis
AD – Atopic Dermatitis
LBW – Low Birth Weight
VLBW – Very Low Birth Weight
ELBW – Extremely Low Birth Weight
PTB – Preterm Birth
SGA – Small for Gestational Age
LGA – Large for Gestational Age
ICS – Inhaled Corticosteroid
ETS – Environmental Tobacco Smoke
SC – Selected Controls
RC – Remaining Controls
ASD – Autism Spectrum Disorders
CA – Congenital Abnormality
WNH – White non – Hispanic
BNH – Black non–Hispanic
SD – Standard Deviation

124

IQR – Interquartile Range
OTC – Over the counter
RRC – Crude relative risk
RRA – Adjusted relative risk

TERMS
Risk factor – Increases the risk of an outcome
Protective factor – Reduces the risk of an outcome
Tend toward significance – p < 0.10
Mildly significant – p < 0.10
Significant – p < 0.05
Not significant – p > 0.10
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APPENDIX J: IRB APPROVAL LETTER
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APPENDIX K: AUTHORIZATION TO USE MEDICAID DATA
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